#,context,disease_name,drug_name,workers_answers,medical_expert1,medical_expert2,medical_expert3,do_id,drug_brand_name,drug_id,label_id,sheet,expert_consensus,inter_agree_experts,medical_expert4,"Final 
(closest option)"
1.0,Nisoldipine extended-release tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.,HYPERTENSION,NISOLDIPINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00401,ce733b39-7857-4538-92d6-1c68a4e4eb75.xml,Indication_treatment,Indication: Treatment,3,,
2.0,"[None, 'Bisoprolol fumarate tablets, USP are indicated in the management of hypertension. They may be used alone or in combination with other antihypertensive agents.']",HYPERTENSION,BISOPROLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00612,c818c38d-ee37-4ceb-b078-611483b4f743.xml,Indication_treatment,Indication: Treatment,3,,
3.0,"Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.",HYPERTENSION,PINDOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00960,d4078b63-30ad-435b-a081-4d90562962b5.xml,Indication_treatment,Indication: Treatment,3,,
4.0,Eprosartan mesylate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers.,HYPERTENSION,EPROSARTAN,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00876,ab531d28-345b-4113-9fde-00cd63ad5b1a.xml,Indication_treatment,Indication: Treatment,3,,
5.0,"[None, 'Labetalol hydrochloride tablets, USP are indicated in the management of hypertension. Labetalol hydrochloride tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.']",HYPERTENSION,LABETALOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00598,78765cc3-27dc-0373-e053-2991aa0a7fe1.xml,Indication_treatment,Indication: Treatment,3,,
7.0,"
                     
Hypertension
Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

                     
Myocardial Infarction
Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.

                     
Migraine
Timolol is indicated for the prophylaxis of migraine headache.",HYPERTENSION,TIMOLOL ANHYDROUS,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00373,87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
8.0,"
                     
Hypertension
Acebutolol hydrochloride capsules, USP are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

                     
Ventricular Arrhythmias
Acebutolol hydrochloride capsules, USP are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats.",HYPERTENSION,ACEBUTOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB01193,8a2799ba-dbd0-4aea-8bb0-35468ffaea94.xml,Indication_treatment,Indication: Treatment,3,,
9.0,"Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). Nicardipine hydrochloride capsules may be used alone or in combination with beta-blockers. 
Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. Nicardipine hydrochloride capsules may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect (See 
         
 
  
DOSAGE AND ADMINISTRATION",HYPERTENSION,NICARDIPINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00622,7e931c00-a198-a65a-e053-2991aa0a44e8.xml,Indication_treatment,Indication: Treatment,3,,
10.0,"Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs.
In clinical studies, Betaxolol Hydrochloride Ophthalmic Solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma.",HYPERTENSION,BETAXOLOL,"i_dont_know
indication_treatment
indication_treatment",Indication: Treatment,Inconsistent,IDK,DOID_10763,,DB00195,aa8fb0a7-d31a-46aa-a207-f0d05afc1672.xml,Indication_treatment,Indication: Treatment,0,,Indication: Treatment
11.0,"Terazosin capsules, USP are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules, USP. The long-term effects of terazosin capsules, USP on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined.
Terazosin capsules, USP are also indicated for the treatment of hypertension. Terazosin capsules, USP can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.",HYPERTENSION,TERAZOSIN,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB01162,5d59b6ec-8f07-ab91-e053-2991aa0adadd.xml,Indication_treatment,Indication: Treatment,3,,
12.0,"Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.
Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.",HYPERTENSION,minoxidil,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00350,66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml,Indication_treatment,Indication: Treatment,3,,
13.0,"Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.
In using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).
Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.",HYPERTENSION,BENAZEPRIL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00542,8fdc8bda-635a-401f-a9b5-8a2a514b429e.xml,Indication_treatment,Indication: Treatment,3,,
14.0,"[None, '\n                     ', 'Hypertension:', None, 'Trandolapril tablets are indicated for the treatment of hypertension. They \nmay be used alone or in combination with other antihypertensive medication such \nas hydrochlorothiazide.', 'In considering the use of trandolapril tablets, it should be noted that in \ncontrolled trials ACE inhibitors (for which adequate data are available) cause a \nhigher rate of angioedema in black than in non-black patients. (See ', '\n                        ', 'Warnings: Angioedema', 'When using trandolapril tablets, consideration should be given to the fact \nthat another angiotensin converting enzyme inhibitor, captopril, has caused \nagranulocytosis, particularly in patients with renal impairment or \ncollagen-vascular disease. Available data are insufficient to show that \ntrandolapril tablets do not have a similar risk. (See ', '\n                        ', 'WARNINGS']",HYPERTENSION,TRANDOLAPRIL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00519,02953299-f03e-4305-9b78-8590f2ad4a46.xml,Indication_treatment,Indication: Treatment,3,,
15.0,"['\n                     ', 'Hypertension', 'Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.', 'In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see ', 'WARNINGS', '\n                     ', 'Angioedema in Black Patients', 'Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.', None]",HYPERTENSION,QUINAPRIL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00881,461bf92c-0ad0-4e99-8542-6dc6bfbde5f1.xml,Indication_treatment,Indication: Treatment,3,,
16.0,"Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Chlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
Chlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia.
Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see 
PRECAUTIONS: Pregnancy",HYPERTENSION,CHLOROTHIAZIDE,"indication_treatment
indication_treatment
contraindication",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00880,2af0405e-71c2-4074-bbd2-41ef19697dd0.xml,Indication_treatment,Indication: Treatment,3,,
17.0,"Fosinopril sodium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see 

                        
DOSAGE AND ADMINISTRATION
In using fosinopril sodium, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril sodium does not have a similar risk (see 

                        
WARNINGS
In considering use of fosinopril sodium, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non- blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see 

                        
WARNINGS
: 

                        
Head and Neck Angioedema
 and 

                        
Intestinal Angioedema",HYPERTENSION,FOSINOPRIL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00492,29914956-c794-4806-b038-f0784b9db3d3.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
18.0,"Methyclothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
Methyclothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Methyclothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
The routine use of diuretics in an otherwise healthy pregnant woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiological and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathological causes, just as they are in the absence of pregnancy (see 
PRECAUTIONS: Pregnancy",HYPERTENSION,METHYCLOTHIAZIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10763,,DB00232,41d6b92e-b9f4-4bcf-9f66-9a36c8e79181.xml,Indication_treatment,Indication: Treatment,3,,
19.0,"['\n                     ', '1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia', 'Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician‰Ûªs judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride injection is intended for short-term use.', '\n                     ', '1.2 Intraoperative and Postoperative Tachycardia and Hypertension', 'Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician‰Ûªs judgment such specific intervention is considered indicated.', None, None, 'Esmolol hydrochloride injection is a beta adrenergic blocker indicated for the short-term treatment of:', '\n                           ', 'Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia\xa0(1.1)', 'Control of perioperative tachycardia and hypertension\xa0(1.2)']",HYPERTENSION,ESMOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00187,e296498d-530b-4346-af09-43008d65c46a.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
21.0,"['Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of:\xa0 ', '\n                           ', 'mild to severe chronic heart failure (\n          \n  \n     ', '1.1', 'left ventricular dysfunction following myocardial infarction in clinically stable patients \n          \n  \n     ', '(1.2)', 'hypertension \n          \n  \n     ', '(1.3)', 'Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization \n         \n \n  ', '[see\xa0', '\n                              ', 'Drug Interactions (7.4)', ' and ', '\n                              ', 'Clinical Studies (14.1)', ']', None, 'Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) \n         \n \n  ', '[see \n          \n  \n   ', 'Clinical Studies (14.2)', None, 'Carvedilol tablets are indicated for the management of essential hypertension \n         \n \n  ', '[see \n          \n  \n   ', 'Clinical Studies (14.3', '14.4)', '[see \n          \n  \n   ', 'Drug Interactions (7.2)']",HYPERTENSION,CARVEDILOL,"indication_treatment
indication_treatment
i_dont_know",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB01136,674ef26b-f8c1-2373-e053-2991aa0a20f6.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
22.0,"
                     
Stable Coronary Artery Disease
Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. 

                     
Hypertension 
Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 
When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See 

                        
WARNINGS
In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See 

                        
WARNINGS

                           
Head and Neck Angioedema",HYPERTENSION,PERINDOPRIL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00790,fbb31482-9ac8-48c6-b814-5d467f22051b.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
23.0,"Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). 
Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. 
In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See 
WARNINGS.
In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See 
WARNINGS, Angioedema.",HYPERTENSION,ramipril,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00178,00bdb48f-8b8f-4cc5-bb63-77213f2279cb.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
24.0,"Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs.
Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure.
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see below).
                                    
PRECAUTIONS
Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
                                    
PRECAUTIONS",HYPERTENSION,INDAPAMIDE,"indication_treatment
contraindication
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00808,d94dd02c-a6c6-4f35-b663-c9bd335fd478.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
25.0,"[None, 'Enalapril maleate is indicated for the treatment of hypertension. ', None, 'Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive.', 'Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, ', '\n                           ', 'Heart Failure, Mortality Trials', ' for details and limitations of survival trials).', 'In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ‰ä_35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, ', '\n                           ', 'Heart Failure, Mortality Trials', ' for details and limitations of survival trials.)', None, None, 'In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.)', None, None, 'In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, ', '\n                           ', 'Head and Neck Angioedema', '.)']",HYPERTENSION,ENALAPRIL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00584,53ac99fe-8ff3-4a6f-b90e-d602e1019acb.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
26.0,"Hydrochlorothiazide Tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
Hydrochlorothiazide Tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Use in pregnancy:
Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia.
Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, PREGNANCY). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.",HYPERTENSION,HYDROCHLOROTHIAZIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00999,414a7bf2-7435-0d18-e054-00144ff8d46c.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
27.0,"INNOPRAN XL

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program‰Ûªs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmåÊHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
INNOPRAN XL is a beta adrenergic blocker indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (
1
Limitation of Use: INNOPRAN XL is not indicated for the treatment of hypertensive emergencies. (
1",HYPERTENSION,PROPRANOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00571,8a9095b7-48a2-4920-9b5e-08a05c21d089.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
28.0,"Felodipine extended-release tablets, USPåÊare indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program‰Ûªs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Felodipine extended-release tablets, USPåÊmay be administered with other antihypertensive agents.",HYPERTENSION,FELODIPINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB01023,6a3461ba-c842-4361-874c-4c2c0215d79e.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
29.0,"['Prazosin Hydrochloride Capsules, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.', None, ""Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)."", None, 'Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.', None, 'Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.', None, 'Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. ', None, 'Prazosin Hydrochloride Capsules, USP can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents.']",HYPERTENSION,PRAZOSIN,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB00457,e64473aa-3115-46d0-94d0-362e48e6ad38.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
30.0,"Nadolol Tablets USP are indicated for the long-term management of patients with angina pectoris.
Nadolol Tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol Tablets USP.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program‰Ûªs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Nadolol Tablets USP may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.",HYPERTENSION,NADOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_10763,,DB01203,af5152c5-3641-4622-9295-02e9ac51b0d5.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
31.0,For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.,MALIGNANT HYPERTENSION,Mecamylamine,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10824,,DB00657,976f404f-4857-4bad-9a3c-9bf3d5ca9f5b.xml,Indication_treatment,Indication: Treatment,3,,
32.0,"Fenoldopam injection is a dopaminergic agonist indicated:

                           

                         
1.1

                              
1.2
Fenoldopam is indicated for in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusion.
Fenoldopam is indicated for in-hospital, short-term (up to 4 hours) reduction in blood pressure [
seeåÊClinical Pharmacology (
12.2",MALIGNANT HYPERTENSION,FENOLDOPAM,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10824,,DB00800,9d4afc95-f504-417b-aa34-e789fe790cf2.xml,Indication_treatment,Indication: Treatment,3,,
36.0,"['Diphenhydramine hydrochloride in the injectable form is effective in adults and pedi\xadatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.', '\n                     ', '\n                        ', 'Antihistaminic', '\n                     ', '\n                        ', None, 'For amelioration of allergic reactions to blood\xa0', 'or plasma, in anaphylaxis as an adjunct to\xa0', 'epinephrine and other standard measures after the acute symptoms have been controlled, and for \xa0other \xa0uncomplicated allergic conditions\xa0', 'of the immediate type when oral therapy is impossible or contraindicated.', '\n                     ', '\n                        ', 'Motion Sickness', 'For active treatment of motion sickness.', '\n                     ', '\n                        ', 'Antiparkinsonism', 'For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows:\xa0', 'parkinsonism in the elderly who are unable to tolerate more potent agents; mild \xa0cases of\xa0', 'parkinsonism in other age groups, and in other\xa0', 'cases of parkinsonism in combination with\xa0', 'centrally acting anticholinergic agents.', None]",MOTION SICKNESS,DIPHENHYDRAMINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2951,,DB01075,d7ac0c39-daaf-4c88-8803-a579e7c9c166.xml,Indication_treatment,Indication: Treatment,3,,
37.0,Olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine.,ULCERATIVE COLITIS,olsalazine,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_8577,,DB01250,23f7e297-0081-4501-abb5-fbe2caf10c10.xml,Indication_treatment,Indication: Treatment,3,,
38.0,"['MESALAMINE delayed-release capsules\xa0is an aminosalicylate indicated for:', '\n                           ', 'Treatment of mildly to moderately active ulcerative colitis in patients\xa05 years of age and older (', '1.1', None, 'Maintenance of remission of ulcerative colitis in adults (', '1.2', 'MESALAMINE delayed-release capsules\xa0is indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older.', 'MESALAMINE delayed-release capsules\xa0is indicated for the maintenance of remission of ulcerative colitis in adults. ']",ULCERATIVE COLITIS,MESALAMINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_8577,,DB00244,6edc85b3-fb4c-4ef6-9b86-12b6b0c02bbb.xml,Indication_treatment,Indication: Treatment,3,,
39.0,"Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and effectiveness of balsalazide beyond 8 weeks in children (ages 5 to 17 years) and 12 weeks in adults have not been established.

                           
Balsalazide is a locally acting aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. (
          
  
     
1
Safety and effectiveness of balsalazide beyond 8 weeks in children (ages 5 to 17 years) and 12 weeks in adults have not been established. (
          
  
     
1",ULCERATIVE COLITIS,BALSALAZIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_8577,,DB01014,62d7e2d4-a1ac-5faf-e053-2a91aa0a8e58.xml,Indication_treatment,Indication: Treatment,3,,
40.0,"Sulfasalazine delayed release tablets are indicated:

                     

                        
a)

                        
b)

                        
c)

                        
d)
1
Sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects.
In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent.",ULCERATIVE COLITIS,SULFASALAZINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_8577,,DB00795,94a14431-9554-48f6-8744-3ccf1f60e5cd.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
41.0,"SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with:

                           
Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate (
1.1
Active psoriatic arthritis (PsA) alone, or in combination with methotrexate (
1.2
Active ankylosing spondylitis (AS) (
1.3
Moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy (
1.4

                                 
inducing and maintaining clinical response
improving endoscopic appearance of the mucosa during induction
inducing clinical remission
achieving and sustaining clinical remission in induction responders
SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis.
SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis.
                           SIMPONI is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine for:

                           
                             inducing and maintaining clinical response
                            improving endoscopic appearance of the mucosa during induction
                             inducing clinical remission
                              achieving and sustaining clinical remission in induction responders 
[see 
Clinical Studies (14.4)",ULCERATIVE COLITIS,golimumab,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_8577,,DB06674,e5f12fc8-7ea4-11e8-8ee4-528d9d46d017.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
42.0,"ENTYVIO is an integrin receptor antagonist indicated for:

                           
Adult Ulcerative Colitis (UC) (
1.1

                           
Adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids:

                                 
inducing and maintaining clinical response
inducing and maintaining clinical remission
improving endoscopic appearance of the mucosa
achieving corticosteroid-free remission

                           
Adult Crohn's Disease (CD) (
1.2

                           
Adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids:

                                 
achieving clinical response
achieving clinical remission
achieving corticosteroid-free remission
ENTYVIO (vedolizumab) is indicated for:

                           
inducing and maintaining clinical response,
inducing and maintaining clinical remission,
improving the endoscopic appearance of the mucosa, and
achieving corticosteroid-free remission
in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
ENTYVIO (vedolizumab) is indicated for:

                           
achieving clinical response, 
achieving clinical remission, and
achieving corticosteroid-free remission
in adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.",ULCERATIVE COLITIS,VEDOLIZUMAB,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_8577,,DB09033,0af85cb3-13fa-44ab-bda2-ad0219abd933.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
43.0,"IMRALDI is a tumor necrosis factor (TNF) blocker indicated for treatment of:


                           

                              
Rheumatoid Arthritis (RA) (
1.1

                              
Juvenile Idiopathic Arthritis (JIA) (
1.2

                              
Psoriatic Arthritis (PsA) (1.3

                              
Ankylosing Spondylitis (AS) (
1.4

                              
Adult Crohn's Disease (CD) (
1.5

                              
Ulcerative Colitis (UC) (
1.6

                              
Plaque Psoriasis (Ps) (
1.7
IMRALDI is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. IMRALDI can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

IMRALDI is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4åÊtoåÊ17åÊyears of age and ‰ä´åÊ30åÊkgåÊ(66åÊlbs). IMRALDI can be used alone or in combination with methotrexate.

IMRALDI is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. IMRALDI can be used alone or in combination with non-biologic DMARDs.

IMRALDI is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

IMRALDI is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. IMRALDI is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

IMRALDI is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to TNF blockers 
[see Clinical Studies (
14.7
IMRALDI is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. IMRALDI should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician 
[see 
Boxed Warning
5",ULCERATIVE COLITIS,Adalimumab,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_8577,,DB00051,803ea065-58db-4434-a3fc-92e57d88e302.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
45.0,"Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. 
Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (‰ä´10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication.
Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery.",KERATITIS,LOTEPREDNOL,"i_dont_know
indication_treatment
indication_treatment",Indication: Symptomatic Relief,Indication: Treatment,IDK,DOID_4677,,DB00873,8ac9f50d-ead0-4ba4-9446-bbb51bfd001f.xml,Indication_treatment,Indication: Treatment,0,,Indication: Treatment
46.0,"['Hydrocortisone Tablets\xa0are indicated in the following conditions.', 'Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer\n                                    ', None, None, None, 'As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:', 'Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis\n                                    ', None, None, None, None, None, None, None, None, 'During an exacerbation or as maintenance therapy in selected cases of:', 'Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis\n                                    ', None, None, 'Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis\n                                    ', None, None, None, None, None, None, 'Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:', 'Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions\n                                    ', None, None, None, None, None, 'Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:', 'Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia\n                                    ', None, None, None, None, None, None, None, None, None, ""Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis\n                                    "", None, None, None, None, 'Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia\n                                    ', None, None, None, None, 'For palliative management of:', 'Leukemias and lymphomas in adults Acute leukemia of childhood\n                                    ', None, 'To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.', 'To tide the patient over a critical period of the disease in:', 'Ulcerative colitis Regional enteritis\n                                    ', None, 'Acute exacerbations of multiple sclerosis', 'Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy', 'Trichinosis with neurologic or myocardial involvement']",KERATITIS,HYDROCORTISONE,"indication_treatment
indication_treatment
indication_treatment",Indication: Symptomatic Relief,Indication: Treatment,IDK,DOID_4677,,DB00741,b0f9b7ea-bac2-427d-92fa-4ccf1b149332.xml,Indication_treatment,Indication: Treatment,0,,Indication: Treatment
47.0,"
                     
Metastatic Prostate Cancer
Nilutamide Tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D
2
For maximum benefit, treatment with Nilutamide Tablets must begin on the same day as or on the day after surgical castration.",PROSTATE CANCER,NILUTAMIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10283,,DB00665,d932db64-a54f-40d3-80ae-5f946c27c355.xml,Indication_treatment,Indication: Treatment,3,,
49.0,"MOTEGRITY‰ã¢ is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
MOTEGRITY‰ã¢ is a serotonin-4 (5-HT
4
1.1",CONSTIPATION,PRUCALOPRIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2089,,DB06480,f5b6251d-bc20-4b2e-998e-02d6b416f71f.xml,Indication_treatment,Indication: Treatment,3,,
50.0,Zafirlukast tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.,ASTHMA,ZAFIRLUKAST,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2841,,DB00549,6e14570e-933d-7f1b-e053-2991aa0aa8a0.xml,Indication_treatment,Indication: Treatment,3,,
51.0,Metaproterenol sulfate tablets are indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm which may occur in association with bronchitis and emphysema.,ASTHMA,METAPROTERENOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2841,,DB00816,a06fd81d-a033-4cc3-abff-797d711303ff.xml,Indication_treatment,Indication: Treatment,3,,
52.0,"Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma.
In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis (see 
DOSAGE AND ADMINISTRATION
In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor (see 
DOSAGE AND ADMINISTRATION",ASTHMA,CROMOLYN,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2841,,DB01003,df2ffa5a-0c12-4601-9f37-7f3670cb95e5.xml,Indication_treatment,Indication: Treatment,3,,
53.0,"['SPIRIVA RESPIMAT is an anticholinergic\nindicated for:', '\n                           ', 'The long-term, once-daily, maintenance treatment of bronchospasm\nassociated with chronic obstructive pulmonary disease (COPD), and\nfor reducing COPD exacerbations (', '1.1', 'The long-term, once-daily, maintenance treatment of asthma\nin patients 6 years of age and older ', '(1.2', 'Limitation of Use:', '\n                           ', 'Not indicated for relief of acute bronchospasm (', '1.1', '1.2', '5.1', 'SPIRIVA RESPIMAT (tiotropium bromide) is\nindicated for the long-term, once-daily, maintenance treatment of\nbronchospasm associated with chronic obstructive pulmonary disease\n(COPD), including chronic bronchitis and emphysema.  SPIRIVA RESPIMAT\nis indicated to reduce exacerbations in COPD patients.', 'Important Limitation of Use:', None, 'SPIRIVA RESPIMAT is a bronchodilator indicated for the long-term,\nonce-daily, maintenance treatment of asthma in patients 6 years of\nage and older.', 'Important\nLimitation of Use:', None]",ASTHMA,TIOTROPIUM,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2841,,DB01409,df865d16-bda0-e8ae-9676-e6c20e22e0c5.xml,Indication_treatment,Indication: Treatment,3,,
54.0,"[None, 'Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: ', '\n                           ', 'Prophylaxis and chronic treatment of asthma in patients 2 years of age and older ', '(1.1)', 'Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ', '(1.2)', 'Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older ', '(1.3)', 'Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. ', 'Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older.', '\n                           ', 'Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp‰Ûªs montelukast tablet products. However, due to Merck Sharp & Dohme Corp‰Ûªs marketing exclusivity rights, this drug product is not labeled with that pediatric information', 'Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. ']",ASTHMA,MONTELUKAST,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_2841,,DB00471,3489a7de-e6b4-4c7c-8837-958d692a29bb.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
55.0,"XOLAIR is an anti-IgE antibody indicated for:

                           
 Moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids (
1.1
 Chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment (
1.2
Limitations of use:

                           
 Not indicated for other allergic conditions or other forms of urticaria. (
1.1
1.2
 Not indicated for acute bronchospasm or status asthmaticus. (
1.1
5.3
XOLAIR is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.

                                 
Limitations of Use:

                                 
XOLAIR is not indicated for the relief of acute bronchospasm or status asthmaticus.
XOLAIR is not indicated for treatment of other allergic conditions.
XOLAIR is indicated for the treatment of adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment.

                                 
Limitation of Use:
XOLAIR is not indicated for treatment of other forms of urticaria.",ASTHMA,OMALIZUMAB,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_2841,,DB00043,633fbb9e-5cd0-418f-8970-992367303ac7.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
56.0,"When oral therapy is not feasible, the 
intramuscular use
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
For palliative management of leukemias and lymphomas.
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
The 
intra-articular or soft tissue administration
The 
intralesional administration
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).",ASTHMA,Betamethasone,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_2841,,DB00443,f3b194d6-1add-42b4-a980-a0539e06bc9e.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
57.0,"['Hydrocortisone Tablets\xa0are indicated in the following conditions.', 'Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer\n                                    ', None, None, None, 'As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:', 'Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis\n                                    ', None, None, None, None, None, None, None, None, 'During an exacerbation or as maintenance therapy in selected cases of:', 'Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis\n                                    ', None, None, 'Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis\n                                    ', None, None, None, None, None, None, 'Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:', 'Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions\n                                    ', None, None, None, None, None, 'Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:', 'Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia\n                                    ', None, None, None, None, None, None, None, None, None, ""Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis\n                                    "", None, None, None, None, 'Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia\n                                    ', None, None, None, None, 'For palliative management of:', 'Leukemias and lymphomas in adults Acute leukemia of childhood\n                                    ', None, 'To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.', 'To tide the patient over a critical period of the disease in:', 'Ulcerative colitis Regional enteritis\n                                    ', None, 'Acute exacerbations of multiple sclerosis', 'Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy', 'Trichinosis with neurologic or myocardial involvement']",ASTHMA,HYDROCORTISONE,"indication_treatment
indication_treatment
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,IDK,DOID_2841,,DB00741,b0f9b7ea-bac2-427d-92fa-4ccf1b149332.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
58.0,"Azelaic acid gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. 
Azelaic acid gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.  Efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. (
1",ROSACEA,AZELAIC ACID,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_8881,,DB00548,c7947a98-396b-4885-9631-ce629e583594.xml,Indication_treatment,Indication: Treatment,3,,
59.0,"Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. 
Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (‰ä´10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication.
Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery.",ROSACEA,LOTEPREDNOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_8881,,DB00873,8ac9f50d-ead0-4ba4-9446-bbb51bfd001f.xml,Indication_treatment,Indication: Treatment,3,,
60.0,Miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,TYPE 2 DIABETES MELLITUS,Miglitol,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9352,,DB00491,17a6135f-ebee-4943-a5bf-b35df3d1ca27.xml,Indication_treatment,Indication: Treatment,3,,
61.0,Tolazamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,TYPE 2 DIABETES MELLITUS,TOLAZAMIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9352,,DB00839,7b33fbac-3018-0b82-e053-2991aa0abc53.xml,Indication_treatment,Indication: Treatment,3,,
62.0,"['ONGLYZA is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ', '(1.1', '14)', '\n                           ', None, '\n                           ', '\n                              ', '‰Û¢', '(1.2)', '\n                              ', '‰Û¢', '(1.2, ', '5.1)', 'ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. [See ', '\n                              ', 'Clinical Studies (14)', 'ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.', 'ONGLYZA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using ONGLYZA. [See ', '\n                              ', 'Warnings and Precautions (5.1)']",TYPE 2 DIABETES MELLITUS,saxagliptin anhydrous,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9352,,DB06335,ecec971e-998c-4773-8081-ab1f5e66b135.xml,Indication_treatment,Indication: Treatment,3,,
63.0,"['TRADJENTA is a dipeptidyl peptidase-4 (DPP-4)\ninhibitor indicated as an adjunct to diet and exercise to improve\nglycemic control in adults with type 2 diabetes mellitus (', '1.1', None, 'Important limitations of use:', '\n                           ', 'Should not be used in patients with type 1 diabetes or for\nthe treatment of diabetic ketoacidosis ', '(1.2)', 'Has not been studied in patients with a history of pancreatitis ', '(1.2)', 'TRADJENTA is indicated as an adjunct to diet and exercise\nto improve glycemic control in adults with type 2 diabetes mellitus ', '\n                              ', '[see Clinical Studies (', '14.1', 'TRADJENTA should\nnot be used in patients with type 1 diabetes or for the treatment\nof diabetic ketoacidosis, as it would not be effective in these settings.', 'TRADJENTA has not been studied in patients\nwith a history of pancreatitis.  It is unknown whether patients with\na history of pancreatitis are at an increased risk for the development\nof pancreatitis while using TRADJENTA ', '[see Warnings and Precautions ', '(5.1)']",TYPE 2 DIABETES MELLITUS,linagliptin,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9352,,DB08882,1135e6c8-c2ae-d958-20ba-6c1eda889aa2.xml,Indication_treatment,Indication: Treatment,3,,
64.0,"['\n                     ', 'Monotherapy and Combination Therapy', '\n                     ', 'Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings ', '[see ', 'Clinical Studies (14)', '.', '\n                     ', None, '\n                     ', 'Important Limitations of Use', '\n                     ', 'Pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.', '\n                     ', 'Use caution in patients with liver disease ', '[see ', 'Warnings and Precautions (5.3)', '.', 'Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (', '1', '14', None, None, '\n                           ', 'Important Limitations of Use:', '\n                           ', 'Not for treatment of type 1 diabetes or diabetic ketoacidosis. (', '1']",TYPE 2 DIABETES MELLITUS,PIOGLITAZONE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9352,,DB01132,c22408fc-7d2c-40d1-be97-90ef6e04005c.xml,Indication_treatment,Indication: Treatment,3,,
65.0,"['\n                     ', None, 'Dicyclomine hydrochloride injection is an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome \n         \n \n    ', '(1)', 'Dicyclomine hydrochloride injection is indicated for the treatment of patients with functional bowel/irritable bowel syndrome.']",IRRITABLE BOWEL SYNDROME,DICYCLOMINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9778,,DB00804,827353c7-d588-04d4-e053-2a91aa0a2f49.xml,Indication_treatment,Indication: Treatment,3,,
66.0,"['LINZESS is indicated in adults for the treatment of:', '\n                     ', 'irritable bowel syndrome with constipation (IBS-C) ', None, 'chronic idiopathic constipation (CIC).', 'LINZESS is a guanylate cyclase-C agonist indicated in adults for treatment of:', '\n                           ', 'Irritable bowel syndrome with constipation. (IBS-C) (', '1', None, 'Chronic idiopathic constipation. (CIC) (', '1']",IRRITABLE BOWEL SYNDROME,linaclotide,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9778,,DB08890,114152bc-d286-4228-9b01-9814473d3875.xml,Indication_treatment,Indication: Treatment,3,,
67.0,"Hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer. It can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Also used in the treatment of infant colic (elixir and drops). Hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a ""drying agent"" in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.",IRRITABLE BOWEL SYNDROME,HYOSCYAMINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9778,,DB00424,61698d95-9cbf-7582-e053-2a91aa0a06a8.xml,Indication_treatment,Indication: Treatment,3,,
68.0,"Marqibo is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.  This indication is based on overall response rate.  Clinical benefit such as improvement in overall survival has not been verified (
1.1
Marqibo
",ACUTE LYMPHOBLASTIC LEUKEMIA,Vincristine,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9952,,DB00541,768cd59b-38a2-4af5-ab91-4d46ae808ab3.xml,Indication_treatment,Indication: Treatment,3,,
69.0,Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.,ACUTE LYMPHOCYTIC LEUKEMIA,CYTARABINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9952,,DB00987,8e757bde-f875-4348-8fbc-8991bc2e1141.xml,Indication_treatment,Indication: Treatment,3,,
70.0,Carteolol Hydrochloride Ophthalmic Solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications.,OPEN-ANGLE GLAUCOMA,CARTEOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1067,,DB00521,42565981-7e64-4080-8195-034fd5ca0565.xml,Indication_treatment,Indication: Treatment,3,,
71.0,"Methazolamide Tablets USPåÊ is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.",OPEN-ANGLE GLAUCOMA,METHAZOLAMIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1067,,DB00703,e191b251-c4c0-46c6-bbb2-710f51a3368e.xml,Indication_treatment,Indication: Treatment,3,,
72.0,"Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery.
Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination.",OPEN-ANGLE GLAUCOMA,PILOCARPINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1067,,DB01085,d2ded29a-448d-4c4a-9307-403836a67da4.xml,Indication_treatment,Indication: Treatment,3,,
73.0,"For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.",GLAUCOMA,ACETAZOLAMIDE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1686,,DB00819,37135ba5-63fd-427f-9b4a-8b7d1009bbca.xml,Indication_treatment,Indication: Treatment,3,,
74.0,Levobunolol HCl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be usedåÊin patients with chronic open-angle glaucoma or ocular hypertension.,OCULAR HYPERTENSION,levobunolol,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9282,,DB01210,8df5bfb3-75d7-4030-b5cb-29ec9ebac0b2.xml,Indication_treatment,Indication: Treatment,3,,
75.0,"Latanoprost Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Latanoprost ophthalmic solution is a prostaglandin F2ë± analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (
1",OCULAR HYPERTENSION,LATANOPROST,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9282,,DB00654,b5057189-a1a0-4282-a86d-0c8c5758fc85.xml,Indication_treatment,Indication: Treatment,3,,
76.0,"Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs.
In clinical studies, Betaxolol Hydrochloride Ophthalmic Solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma.",OCULAR HYPERTENSION,BETAXOLOL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9282,,DB00195,aa8fb0a7-d31a-46aa-a207-f0d05afc1672.xml,Indication_treatment,Indication: Treatment,3,,
77.0,"Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.",HYPOPARATHYROIDISM,ERGOCALCIFEROL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_11199,,DB00153,876fef38-0e7e-e076-e053-2a95a90a3565.xml,Indication_treatment,Indication: Treatment,3,,
78.0,"Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.",RICKETS,ERGOCALCIFEROL,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_10609,,DB00153,876fef38-0e7e-e076-e053-2a95a90a3565.xml,Indication_treatment,Indication: Treatment,3,,
79.0,"NEUPRO is a dopamine agonist indicated for the treatment of:

                           
Parkinson's disease (
1.1
Moderate-to-severe primary Restless Legs Syndrome (
1.2
NEUPRO is indicated for the treatment of Parkinson's disease.
NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.",PARKINSON'S DISEASE,rotigotine,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_14330,,DB05271,a6964835-dc96-4b22-8b64-464a42f6cdf2.xml,Indication_treatment,Indication: Treatment,3,,
80.0,"INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.
INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa (
         
 
    
1",PARKINSON'S DISEASE,LEVODOPA,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_14330,,DB01235,7e95ddcc-7fe7-8b52-e053-2a91aa0a2984.xml,Indication_treatment,Indication: Treatment,3,,
81.0,"APOKYN (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications 
[see 
Clinical Studies (14)
APOKYN is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) associated with advanced Parkinson's disease (
1",PARKINSON'S DISEASE,APOMORPHINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_14330,,DB00714,f4356cec-5223-42f2-b26e-c736ec2c308a.xml,Indication_treatment,Indication: Treatment,3,,
82.0,"Cyclosporine Capsules USP (Modified) are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine Capsules USP (Modified) have been used in combination with azathioprine and corticosteroids.
Cyclosporine Capsules USP (Modified) are indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine Capsules USP (Modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone.
Cyclosporine Capsules USP (Modified) are indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated.
While rebound rarely occurs, most patients will experience relapse with Cyclosporine Capsules USP (Modified) as with other therapies upon cessation of treatment.",RHEUMATOID ARTHRITIS,CYCLOSPORINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_7148,,DB00091,712d2ef2-c795-496a-b4c2-f3e30789dd01.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
84.0,"['Carefully consider the potential benefits and risks of ibuprofen oral suspension and other treatment options before deciding to use ibuprofen oral suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ', '\n                        ', 'WARNINGS', None, '\n                     ', 'In Pediatric Patients, Ibuprofen Oral Suspension is indicated:', '\n                     ', 'For reduction of fever in patients aged 6 months up to 2 years of age.', 'For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. ', 'For relief of signs and symptoms of juvenile arthritis. ', None, '\n                     ', 'In Adults, Ibuprofen Oral Suspension is indicated:', '\n                     ', 'For treatment of primary dysmenorrhea.', 'For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.', None, 'Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended (see ', '\n                        ', 'PRECAUTIONS-Drug Interactions']",RHEUMATOID ARTHRITIS,IBUPROFEN,"indication_symptomatic_relief
indication_treatment
indication_treatment",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB01050,d2e35cfc-1c17-456f-8608-5d2c6f7bcb02.xml,Indication_treatment,Indication: Symptomatic Relief,3,,
85.0,"RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies.
Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.
When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage.
In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy.",RHEUMATOID ARTHRITIS,auranofin,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_7148,,DB00995,6008addc-7f8e-45bb-8aec-54dd54a788ac.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
86.0,"['Enter section text here', '\n                           ', None, '\n                           ', 'Treatment of schizophrenia in adults (', '1.1', 'Alone, or in combination with lithium or valproate, for the short-term \ntreatment of acute manic or mixed episodes associated with Bipolar I Disorder in \nadults (', '1.2', 'Due to Janssen Pharmaceuticals Corporation‰Ûªs marketing exclusivity rights; \nthis drug product is not labeled for use in pediatric patients with \nschizophrenia or bipolar mania. (', '1.1', '1.2', 'Treatment of irritability associated with autistic disorder in children and \nadolescents aged 5-16 years (', '1.3', None, '\n                           ', None, 'Risperidone tablets are indicated for the acute and maintenance treatment of \nschizophrenia ', '[see ', 'Clinical Studies \n(14.1)', 'Adolescents', 'Due to Janssen Pharmaceuticals Corporation‰Ûªs marketing exclusivity rights, \nthis drug product is not labeled for use in pediatric patients with \nschizophrenia .Pediatric use information for the treatment of pediatric patients \nwith schizophrenia, 13 to 17 years of age, is approved for Janssen \nPharmaceuticals Corporation‰Ûªs risperidone drug products.', '\n                           ', None, 'Risperidone tablets are indicated for the short-term treatment of acute manic \nor mixed episodes associated with Bipolar I Disorder in adults ', '[see ', 'Clinical Studies (14.2)', 'Due to Janssen Pharmaceuticals Corporation‰Ûªs marketing exclusivity rights, \nthis drug product is not labeled for use in pediatric patients with bipolar \nmania. Pediatric use information for the treatment of pediatric patients with \nbipolar mania, 10 to 17 years of age, is approved for Janssen Pharmaceuticals \nCorporation‰Ûªs risperidone drug products.', 'Combination Therapy ‰ÛÒ Adults', 'The combination of risperidone with lithium or valproate is indicated for the \nshort-term treatment of acute manic or mixed episodes associated with Bipolar I \nDisorder ', '[see ', 'Clinical Studies \n(14.3)', '\n                           ', None, 'Risperidone tablets are indicated for the treatment of irritability \nassociated with autistic disorder in children and adolescents aged 5-16 years, \nincluding symptoms of aggression towards others, deliberate self-injuriousness, \ntemper tantrums, and quickly changing moods ', '[see Clinical \nStudies (', '14.4']",SCHIZOPHRENIA,RISPERIDONE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,IDK,DOID_5419,,DB00734,c031d46a-1f80-4600-ab2e-ff0b6e267e2a.xml,Indication_treatment,Indication: Treatment,2,Indication: Treatment,
89.0,"['OFEV is indicated for the treatment of idiopathic\npulmonary fibrosis (IPF).', 'OFEV is a kinase inhibitor indicated\nfor the treatment of idiopathic pulmonary fibrosis (IPF). (', '1', None]",IPF,NINTEDANIB,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2797,,DB09079,c00a7965-cd50-3326-5b26-d06d46729939.xml,Indication_treatment,Indication: Treatment,3,,
90.0,"OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:

                           
Adult patients with active psoriatic arthritis (
1.1
Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy (
1.2
OTEZLA is indicated for the treatment of adult patients with active psoriatic arthritis.
OTEZLA is indicated for the treatment of  patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.",PSORIATIC ARTHRITIS,APREMILAST,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9008,,DB05676,f7608fb8-2cd4-4295-a7aa-bd82fc1f2945.xml,Indication_treatment,Indication: Treatment,3,,
91.0,"FIRAZYR

FIRAZYR is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. (
1",HEREDITARY ANGIOEDEMA,icatibant,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_14735,,DB06196,c3e90288-9ebb-41f2-a58c-fffec2cf5172.xml,Indication_treatment,Indication: Treatment,3,,
92.0,"GYNAZOLE ‰Û¢ 1 Butoconazole Nitrate Vaginal Cream USP, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by 
Candida
CLINICAL STUDIES

                     
Note: 
PRECAUTIONS - Pregnancy",VULVOVAGINAL CANDIDIASIS,BUTOCONAZOLE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2272,,DB00639,3d7960d0-4aa9-4033-bf2e-4d0c2064e71a.xml,Indication_treatment,Indication: Treatment,3,,
93.0,"Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.
",VULVOVAGINAL CANDIDIASIS,TERCONAZOLE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2272,,DB00251,8d38d308-d218-4f4e-b7bf-e29acb3a8c56.xml,Indication_treatment,Indication: Treatment,3,,
94.0,"Miconazole Nitrate Vaginal Suppositories USP, 200 mg are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy has not been established. As miconazole nitrate is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis (
Trichomonas 
Haemophilus vaginalis [Gardnerella]",VULVOVAGINAL CANDIDIASIS,MICONAZOLE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_2272,,DB01110,8894a46c-6e2e-402e-b93d-bbfaf6ecb6fa.xml,Indication_treatment,Indication: Treatment,3,,
95.0,"Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.
Temsirolimus injection is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. (
         
 
    
1",RENAL CELL CARCINOMA,TEMSIROLIMUS,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_4450,,DB06287,736ae550-f75e-98f6-e053-2991aa0a5f87.xml,Indication_treatment,Indication: Treatment,3,,
96.0,"INLYTA is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
INLYTA is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. (
1",RENAL CELL CARCINOMA,AXITINIB,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_4450,,DB06626,50eb7178-6a41-45da-85d0-70c16e5b7a03.xml,Indication_treatment,Indication: Treatment,3,,
97.0,"YONDELIS

[see 
Clinical Studies (14)
YONDELIS is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (
1",LEIOMYOSARCOMA,Trabectedin,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1967,,DB05109,a7038afa-7ea8-11e8-929f-3b9e9d46d017.xml,Indication_treatment,Indication: Treatment,3,,
98.0,"Idarubicin Hydrochloride Injection, USPåÊin combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.",ACUTE MYELOID LEUKEMIA,IDARUBICIN,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9119,,DB01177,23c8614b-c992-4842-9807-c5681c099546.xml,Indication_treatment,Indication: Treatment,3,,
99.0,"['Doxorubicin hydrochloride (HCl) for injection is an anthracycline topoisomerase II inhibitor indicated: ', '\n                           ', 'as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (', '1.1', 'for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms‰Ûª tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (', '1.2', None, None, 'Doxorubicin HCl for injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ', '[see ', 'Clinical Studies (14)', '\n                           ', None, None, None, 'Doxorubicin HCl for injection is indicated for the treatment of ', '\n                           ', 'acute lymphoblastic leukemia ', 'acute myeloblastic leukemia ', 'Hodgkin lymphoma ', 'non-Hodgkin lymphoma (NHL) ', 'metastatic breast cancer ', 'metastatic Wilms‰Ûª tumor ', 'metastatic neuroblastoma ', 'metastatic soft tissue sarcoma ', 'metastatic bone sarcoma ', 'metastatic ovarian carcinoma ', 'metastatic transitional cell bladder carcinoma ', 'metastatic thyroid carcinoma ', 'metastatic gastric carcinoma ', 'metastatic bronchogenic carcinoma ', None, None]",ACUTE MYELOBLASTIC LEUKEMIA,DOXORUBICIN,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9119,,DB00997,f7aba497-daea-4b5d-bc2d-687ea6f20243.xml,Indication_treatment,Indication: Treatment,3,,
100.0,"SYLATRON
‰ã¢
SYLATRON is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. (
1",MELANOMA,peginterferon alfa-2b,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1909,,DB00022,0c89b700-c744-4001-a10b-0622863557d6.xml,Indication_treatment,Indication: Treatment,3,,
101.0,"Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection, USP is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.",MALIGNANT MELANOMA,DACARBAZINE,"indication_treatment
indication_treatment
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_1909,,DB00851,fbcc23f2-6a56-4dd2-bf9f-79a9f5dbf6a2.xml,Indication_treatment,Indication: Treatment,3,,
1.0,"Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes and make coughs more productive. Helps loosen phlegm and thin bronchial secretions in patients with stable chronic bronchitis.",CHRONIC BRONCHITIS,GUAIFENESIN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_6132,,DB00874,78987a51-82f7-4ca6-80ad-fa22d1f3e11a.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
2.0,Levobunolol HCl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be usedåÊin patients with chronic open-angle glaucoma or ocular hypertension.,OPEN-ANGLE GLAUCOMA,levobunolol,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,Inconsistent,DOID_1067,,DB01210,8df5bfb3-75d7-4030-b5cb-29ec9ebac0b2.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
3.0,"[None, 'Bimatoprost ophthalmic solution, 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.', 'Bimatoprost ophthalmic solution, 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.']",OCULAR HYPERTENSION,BIMATOPROST,"effect
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,Indication: Symptomatic Relief,DOID_9282,,DB00905,bb539c8f-cb07-453d-8aaf-7bc94b7687d3.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
4.0,"Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Travoprost Ophthalmic Solution USP, 0.004% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 
1",OCULAR HYPERTENSION,TRAVOPROST,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,Inconsistent,DOID_9282,,DB00287,f56bbe0b-fa82-46af-924f-9122bd4f7089.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
5.0,"Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

The IOP lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.

Brimonidine tartrate ophthalmic solution 0.2% is an alpha adrenergic agonist indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (
1",OCULAR HYPERTENSION,Brimonidine,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,Inconsistent,DOID_9282,,DB00484,c2d7435f-8989-4c1f-af7d-b42d52cf952a.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
6.0,"Tolcapone tablets, USP is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone tablets, USP should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because tolcapone tablets, USP, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from tolcapone tablets, USP.
The effectiveness of tolcapone tablets, USP was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see 
CLINICAL PHARMACOLOGY
Clinical Studies",PARKINSON'S DISEASE,TOLCAPONE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_treatment",Indication: Symptomatic Relief,Indication: Treatment,Inconsistent,DOID_14330,,DB00323,658c55ce-6b19-4c53-8563-d03ea83f7ccd.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
8.0,,PARALYSIS AGITANS,CARBIDOPA ANHYDROUS,"indication_symptomatic_relief
indication_symptomatic_relief
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_14330,,DB00190,272d12b4-b3bc-4891-9da5-189d0c961ae4.xml,indication_symptomatic_relief,Indication: Treatment,3,,
9.0,"Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
                            

                        
WARNINGS",RHEUMATOID ARTHRITIS,SALSALATE,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB01399,e495fb85-bf37-4c6f-a9c9-31fd73dbe373.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
10.0,"Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 
WARNINGS
Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following:
1. Mild to moderate pain
2. Osteoarthritis
3. Rheumatoid arthritis",RHEUMATOID ARTHRITIS,DIFLUNISAL,"indication_treatment
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Treatment,DOID_7148,,DB00861,bffd61d6-af2e-46ae-bbca-96f150483953.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
11.0,"[None, 'Carefully consider the potential benefits and risks of \nflurbiprofen tablets and other treatment options before deciding to use \nflurbiprofen tablets. Use the lowest effective dose for the shortest duration \nconsistent with individual patient treatment goals (see ', 'WARNINGS', 'Flurbiprofen tablets are indicated:', '\n                     ', 'For relief of the signs and symptoms of rheumatoid arthritis. \n', 'For relief of the signs and symptoms of osteoarthritis.']",RHEUMATOID ARTHRITIS,FLURBIPROFEN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00712,f0d1d9cb-3a95-4389-8cc7-29634a1f227c.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
12.0,"Carefully consider the potential benefits and risks of nabumetone tablets USP and other treatment options before deciding to use nabumetone tablets USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 

                        
WARNINGS 
Nabumetone tablets USP are indicated:
* For relief of the signs and symptoms of rheumatoid arthritis. 
* For relief of the signs and symptoms of osteoarthritis.",RHEUMATOID ARTHRITIS,NABUMETONE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00461,a34aebce-f0b6-4341-8c7f-49bdd1c06fe9.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
13.0,"['Piroxicam capsule, is indicated:', None, '\n                     ', 'For relief of the signs and symptoms of osteoarthritis.', 'For relief of the signs and symptoms of rheumatoid arthritis.', 'Piroxicam capsule,is a nonste roidal anti -infla mmato ry d rug indicated for', '\n                           ', 'Relief of the signs and sy mpt o ms of osteoarthritis (OA) (\n          \n  \n     ', '1', 'Relief of the signs and sy mpto ms of rheu m atoid arthritis (RA) (\n          \n  \n     ', '1']",RHEUMATOID ARTHRITIS,PIROXICAM,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00554,895e8bb5-3f29-96f8-e053-2a95a90ab025.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
14.0,"Carefully consider the potential benefits and risks of etodolac extended-release tablets, USP and other treatment options before deciding to use etodolac extended-release tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 

                        
WARNINGS
Etodolac extended-release tablets, USP are indicated:
*åÊåÊåÊ For relief of signs and symptoms of juvenile arthritis
*åÊåÊåÊ For relief of the signs and symptoms of rheumatoid arthritis
*åÊåÊåÊ For relief of the signs and symptoms of osteoarthritis",RHEUMATOID ARTHRITIS,ETODOLAC,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00749,8bc073da-7e01-4e0f-91bf-e5440b31bd1f.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
15.0,"['Oxaprozin tablets are indicated: ', '\n                     ', 'For relief of the signs and symptoms of osteoarthritis ', 'For relief of the signs and symptoms of rheumatoid arthritis ', 'For relief of the signs and symptoms of juvenile rheumatoid arthritis ', None, 'Oxaprozin is a non-steroidal anti-inflammatory drug indicated for: ', '\n                           ', 'Relief of signs and symptoms of Osteoarthritis (OA) ', '(1) ', 'Relief of signs and symptoms of Rheumatoid Arthritis (RA) ', '(1)', 'Relief of signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) ', '(1)', None]",RHEUMATOID ARTHRITIS,OXAPROZIN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00991,c9f27654-c926-4a7e-b4fa-685ed58ea778.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
16.0,"['FENOPROFEN CALCIUM, USP is indicated for:', '\n                     ', 'Relief of mild to moderate pain in adults.', 'Relief of the signs and symptoms of rheumatoid arthrites.', 'Relief of the signs and symptoms of osteoarthritis.', None, 'FENOPROFEN CALCIUM, USP is a nonsteroidal anti-inflammatory drug indicated for:', None, '\n                           ', 'Relief of mild to moderate pain in adults. ( \n     \n          \n  \n     ', '1', 'Relief of the signs and symptoms of rheumatoid arthritis. ( \n     \n          \n  \n     ', '1', 'Relief of the signs and symptoms of osteoarthritis. ( \n     \n          \n  \n     ', '1']",RHEUMATOID ARTHRITIS,FENOPROFEN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00573,799d4149-5bc6-4843-e053-2a91aa0ade16.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
17.0,"Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 
WARNINGS
Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see 
CLINICAL PHARMACOLOGY: Pharmacokinetics
Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea.",RHEUMATOID ARTHRITIS,KETOPROFEN,"indication_symptomatic_relief
contraindication
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB01009,9bc31f67-cfce-4ad6-9c07-3845ead3542c.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
18.0,"Carefully consider the potential benefits and risks of tolmetin sodium capsules, USP and other treatment options before deciding to use tolmetin sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 
WARNINGS
Tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease.
Tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age (see 
PRECAUTIONS: Pediatric Use
DOSAGE AND ADMINISTRATION",RHEUMATOID ARTHRITIS,TOLMETIN,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00500,3d31d157-0b80-4d2d-ba34-b833b082e45f.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
19.0,"['Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  ', '\n                        ', 'WARNINGS', 'Sulindac tablets,\xa0USP\xa0are indicated for acute or\xa0long-term use in the relief of signs and symptoms of the following:', '\n                     ', '\n                        ', 'Osteoarthritis', '\n                        ', 'Rheumatoid arthritis**', '\n                        ', 'Ankylosing spondylitis', '\n                        ', 'Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis)', '\n                        ', 'Acute gouty arthritis', '\n                     ', None, '\n                        ', '\n                           ', '\xa0** The safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the American Rheumatism Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care).']",RHEUMATOID ARTHRITIS,SULINDAC,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00605,4e183e42-5781-562e-e054-00144ff88e88.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
20.0,"['Carefully consider the potential benefits and risks of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension and other treatment options before deciding to use NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  ', '\n                        ', 'WARNINGS', 'Naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is indicated:', '\n                     ', 'For the relief of the signs and symptoms of rheumatoid arthritis\n        \n  \n   ', None, 'For the relief of the signs and symptoms of osteoarthritis\n        \n  \n   ', None, 'For the relief of the signs and symptoms of ankylosing spondylitis\n        \n  \n   ', None, 'For the relief of the signs and symptoms of juvenile arthritis', 'Naproxen as NAPROSYN Suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient‰Ûªs weight.', 'Naproxen as NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension is also indicated:', '\n                     ', 'For relief of the signs and symptoms of tendonitis\n        \n  \n   ', None, 'For relief of the signs and symptoms of bursitis\n        \n  \n   ', None, 'For relief of the signs and symptoms of acute gout\n        \n  \n   ', None, 'For the management of pain\n        \n  \n   ', None, 'For the management of primary dysmenorrhea', 'EC-NAPROSYN is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see \n       \n \n  ', '\n                        ', 'CLINICAL PHARMACOLOGY', '\n                        ', 'DOSAGE AND ADMINISTRATION']",RHEUMATOID ARTHRITIS,NAPROXEN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7148,,DB00788,7cd6b7bd-2af1-aaf3-e053-2991aa0aa9a3.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
21.0,"Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
                            

                        
WARNINGS",ARTHRITIS,SALSALATE,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_848,,DB01399,e495fb85-bf37-4c6f-a9c9-31fd73dbe373.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
22.0,"['Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  ', '\n                        ', 'WARNINGS', 'Sulindac tablets,\xa0USP\xa0are indicated for acute or\xa0long-term use in the relief of signs and symptoms of the following:', '\n                     ', '\n                        ', 'Osteoarthritis', '\n                        ', 'Rheumatoid arthritis**', '\n                        ', 'Ankylosing spondylitis', '\n                        ', 'Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis)', '\n                        ', 'Acute gouty arthritis', '\n                     ', None, '\n                        ', '\n                           ', '\xa0** The safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the American Rheumatism Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care).']",ANKYLOSING SPONDYLITIS,SULINDAC,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7147,,DB00605,4e183e42-5781-562e-e054-00144ff88e88.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
24.0,"['Carefully consider the potential benefits and risks of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension and other treatment options before deciding to use NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  ', '\n                        ', 'WARNINGS', 'Naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is indicated:', '\n                     ', 'For the relief of the signs and symptoms of rheumatoid arthritis\n        \n  \n   ', None, 'For the relief of the signs and symptoms of osteoarthritis\n        \n  \n   ', None, 'For the relief of the signs and symptoms of ankylosing spondylitis\n        \n  \n   ', None, 'For the relief of the signs and symptoms of juvenile arthritis', 'Naproxen as NAPROSYN Suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient‰Ûªs weight.', 'Naproxen as NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension is also indicated:', '\n                     ', 'For relief of the signs and symptoms of tendonitis\n        \n  \n   ', None, 'For relief of the signs and symptoms of bursitis\n        \n  \n   ', None, 'For relief of the signs and symptoms of acute gout\n        \n  \n   ', None, 'For the management of pain\n        \n  \n   ', None, 'For the management of primary dysmenorrhea', 'EC-NAPROSYN is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see \n       \n \n  ', '\n                        ', 'CLINICAL PHARMACOLOGY', '\n                        ', 'DOSAGE AND ADMINISTRATION']",ANKYLOSING SPONDYLITIS,NAPROXEN,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_7147,,DB00788,7cd6b7bd-2af1-aaf3-e053-2991aa0aa9a3.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
25.0,"['NEUPOGEN is a leukocyte growth factor indicated to ', '\n                           ', 'Decrease the incidence of infection‰Û_ as manifested by febrile neutropenia‰Û_ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (', '1.1', None, 'Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) (', '1.2', None, 'Reduce the duration of neutropenia and neutropenia-related clinical sequelae‰Û_\xa0e.g.‰Û_ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) (', '1.3', None, 'Mobilize\xa0autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (', '1.4', None, 'Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‰Û_ fever‰Û_ infections‰Û_ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‰Û_ cyclic neutropenia‰Û_ or idiopathic neutropenia (', '1.5', None, 'Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) (', '1.6', 'NEUPOGEN is indicated to decrease the incidence of infection‰Û_ as manifested by febrile neutropenia‰Û_ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ', '[see Clinical Studies (', '\n                              ', '14.1', ')]', 'NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ', '[see Clinical Studies (', '\n                              ', '14.2', ')]', 'NEUPOGEN is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‰Û_ e.g.‰Û_ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation ', '[see Clinical Studies (', '\n                              ', '14.3', ')]', 'NEUPOGEN is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis', ' [see Clinical Studies (', '\n                              ', '14.4', ')]', 'NEUPOGEN is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‰Û_ fever‰Û_ infections‰Û_ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‰Û_ cyclic neutropenia‰Û_ or idiopathic neutropenia ', '[see Clinical Studies (', '\n                              ', '14.5', ')]', 'NEUPOGEN\xa0is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation ', '[see Clinical Studies (', '\n                              ', '14.6', ')]', '\xa0']",NEUTROPENIA,FILGRASTIM,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,IDK,DOID_1227,,DB00099,6c14d827-1d18-4657-80ef-3da115da7e2d.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
26.0,"Fabrazyme

Fabrazyme is indicated for use in patients with Fabry disease. Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types. (
1",FABRY DISEASE,AGALSIDASE BETA,"indication_symptomatic_relief
indication_symptomatic_relief
indication_treatment",Indication: Treatment,Indication: Treatment,Indication: Symptomatic Relief,DOID_14499,,DB00103,390a17ad-7962-44b9-87e1-92df9852df09.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
27.0,"['Dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium capsules are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.', 'If improvement occurs, it will ordinarily occur within the dosage titration (see ', '\n                              ', 'DOSAGE AND ADMINISTRATION', 'Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsule therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.', ""A decision to continue the administration of dantrolene sodium capsules on a long-term basis is justified if introduction of the drug into the patient's regimen:"", '\n                           ', '\xa0\xa0produces a significant reduction in painful and/or disabling spasticity such as clonus, or', None, '\xa0\xa0permits a significant reduction in the intensity and/or degree of nursing care required, or', None, '\xa0\xa0rids the patient of any annoying manifestation of spasticity considered important by the patient himself.', 'Oral dantrolene sodium capsules are also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for intravenous dantrolene sodium.', 'Oral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.']",MULTIPLE SCLEROSIS,DANTROLENE,"contraindication
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,IDK,DOID_2377,,DB01219,cbece5e5-72b3-433f-84ae-03013ce93454.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
28.0,"Hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer. It can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Also used in the treatment of infant colic (elixir and drops). Hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a ""drying agent"" in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.",RHINITIS,HYOSCYAMINE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_4483,,DB00424,61698d95-9cbf-7582-e053-2a91aa0a06a8.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
32.0,"['\n                     ', '1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia', 'Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician‰Ûªs judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride injection is intended for short-term use.', '\n                     ', '1.2 Intraoperative and Postoperative Tachycardia and Hypertension', 'Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician‰Ûªs judgment such specific intervention is considered indicated.', None, None, 'Esmolol hydrochloride injection is a beta adrenergic blocker indicated for the short-term treatment of:', '\n                           ', 'Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia\xa0(1.1)', 'Control of perioperative tachycardia and hypertension\xa0(1.2)']",ATRIAL FIBRILLATION,ESMOLOL,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_0060224,,DB00187,e296498d-530b-4346-af09-43008d65c46a.xml,indication_symptomatic_relief,Indication: Treatment,3,,
34.0,"['Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n       \n \n  ', '\n                        ', 'WARNINGS', 'Sulindac tablets,\xa0USP\xa0are indicated for acute or\xa0long-term use in the relief of signs and symptoms of the following:', '\n                     ', '\n                        ', 'Osteoarthritis', '\n                        ', 'Rheumatoid arthritis**', '\n                        ', 'Ankylosing spondylitis', '\n                        ', 'Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis)', '\n                        ', 'Acute gouty arthritis', '\n                     ', None, '\n                        ', '\n                           ', '\xa0** The safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the American Rheumatism Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care).']",GOUTY ARTHRITIS,SULINDAC,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_13189,,DB00605,4e183e42-5781-562e-e054-00144ff88e88.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
35.0,"When oral therapy is not feasible, the 
intramuscular use
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
For palliative management of leukemias and lymphomas.
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
The 
intra-articular or soft tissue administration
The 
intralesional administration
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).",GOUTY ARTHRITIS,Betamethasone,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Treatment,Indication: Symptomatic Relief,DOID_13189,,DB00443,f3b194d6-1add-42b4-a980-a0539e06bc9e.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
36.0,"Cilostazol tablets, USP are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.
Cilostazol tablets, USP are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance (
1",INTERMITTENT CLAUDICATION,CILOSTAZOL,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_3669,,DB01166,05a33095-18cb-4628-811d-ba56f7e07820.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
37.0,"Azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.
Azelastine hydrochloride nasal spray is an H1-receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older. (
1",VASOMOTOR RHINITIS,AZELASTINE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_4730,,DB00972,50bc8185-bcd7-20a7-abe8-cf06810e6a79.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
38.0,"Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows:

                           
For the relief of symptoms associated with cerebrovascular insufficiency.
In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. 
Final classification of the less-than-effective indications requires further investigation.",RAYNAUD'S DISEASE,Isoxsuprine,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_10300,,DB08941,4c461b5a-4023-486c-93ee-d641b499df4b.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
39.0,"Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.
In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.
As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures (see 

                        
WARNINGS
Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus.
Injectable diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures.
Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedure.",TETANUS,DIAZEPAM,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Symptomatic Relief,Indication: Symptomatic Relief,DOID_11338,,DB00829,4e800d0d-2181-49b1-a2c8-4c6c49edd83a.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,3,,
41.0,"Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. 
Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
Bumetanide is contraindicated in anuria. Although bumetanide tablets can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide tablets. Bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected. Bumetanide is contraindicated in patients hypersensitive to this drug.",NEPHROTIC SYNDROME,BUMETANIDE,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Treatment,DOID_1184,,DB00887,a94471b1-a588-44e7-b17b-b99f5c3ba31d.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
42.0,"Mitoxantrone injection USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone injection USP (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. 
The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. 
Mitoxantrone injection USP (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. 
Mitoxantrone injection USP (concentrate) in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. ",RELAPSING-REMITTING MULTIPLE SCLEROSIS,MITOXANTRONE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Treatment,Indication: Symptomatic Relief,DOID_2378,,DB01204,031f9934-217e-40c4-b623-92a44b5831ac.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
43.0,"The use of metoclopramide tablets, USP is recommended for adults only. Therapy should not exceed 12 weeks in duration.
Symptomatic Gastroesophageal Reflux:  Metoclopramide tablets, USP are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.
The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically.
Diabetic Gastroparesis (Diabetic Gastric Stasis):  Metoclopramide tablets, USP are indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more.",GASTROPARESIS,METOCLOPRAMIDE,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Treatment,Inconsistent,DOID_11914,,DB01233,42a00e68-d00d-219a-e054-00144ff88e88.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
44.0,"Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation.
Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only.",RHINITIS,CLEMASTINE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_4483,,DB00283,82dfc095-30e3-441a-a9b6-5276a049f5a6.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
46.0,"['Oxaprozin tablets are indicated: ', '\n                     ', 'For relief of the signs and symptoms of osteoarthritis ', 'For relief of the signs and symptoms of rheumatoid arthritis ', 'For relief of the signs and symptoms of juvenile rheumatoid arthritis ', None, 'Oxaprozin is a non-steroidal anti-inflammatory drug indicated for: ', '\n                           ', 'Relief of signs and symptoms of Osteoarthritis (OA) ', '(1) ', 'Relief of signs and symptoms of Rheumatoid Arthritis (RA) ', '(1)', 'Relief of signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) ', '(1)', None]",ARTHRITIS,OXAPROZIN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_848,,DB00991,c9f27654-c926-4a7e-b4fa-685ed58ea778.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
47.0,"Carefully consider the potential benefits and risks of tolmetin sodium capsules, USP and other treatment options before deciding to use tolmetin sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 
WARNINGS
Tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease.
Tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age (see 
PRECAUTIONS: Pediatric Use
DOSAGE AND ADMINISTRATION",ARTHRITIS,TOLMETIN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_848,,DB00500,3d31d157-0b80-4d2d-ba34-b833b082e45f.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
48.0,"Mometasone Furoate Monohydrate Nasal Spray is a corticosteroid indicated for:
1. Treatment of Nasal Symptoms of Allergic Rhinitis in patients ‰ä´2 years of age (
1.1
2. Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ‰ä´2 years of age (
1.2
3. Prophylaxis of Seasonal Allergic Rhinitis in patients ‰ä´12 years of age (
1.3
4. Treatment of Nasal Polyps in patients ‰ä´18 years of age (
1.4
Mometasone Furoate Monohydrate Nasal Spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Mometasone Furoate Monohydrate Nasal Spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Mometasone Furoate Monohydrate Nasal Spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older.
Mometasone Furoate Monohydrate Nasal Spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older.",RHINITIS,Mometasone,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Inconsistent,DOID_4483,,DB00764,0be7313b-8485-4264-bed8-40c57dc904f3.xml,indication_symptomatic_relief,Indication: Treatment,0,,Indication: Treatment
49.0,"Cetirizine hydrochloride syrup is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. 
Cetirizine hydrochloride syrup is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months to 5 years of age. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.",RHINITIS,CETIRIZINE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_4483,,DB00341,a0fe22f2-9063-49d4-831f-2271643b7d0a.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
50.0,"Hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer. It can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Also used in the treatment of infant colic (elixir and drops). Hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a ""drying agent"" in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.",DIVERTICULITIS,HYOSCYAMINE,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_7475,,DB00424,61698d95-9cbf-7582-e053-2a91aa0a06a8.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
51.0,"Oxandrolone Tablets, USP are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see 

                        
DOSAGE AND ADMINISTRATION",OSTEOPOROSIS,Oxandrolone,"indication_symptomatic_relief
indication_symptomatic_relief
indication_treatment",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_11476,,DB00621,24672ff6-88f0-4cb5-95c0-12d9907534f5.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
52.0,Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies.,DIARRHEA,LOPERAMIDE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_13250,,DB00836,3fc80822-6257-4937-e054-00144ff8d46c.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
53.0,Flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution should not be used in the presence of untreated localized infection involving the nasal mucosa.,RHINITIS,FLUNISOLIDE ANHYDROUS,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_4483,,DB00180,3f3d300d-a843-4da8-90d1-7a1a4c283c51.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
54.0,"[None, 'Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: ', '\n                           ', 'Prophylaxis and chronic treatment of asthma in patients 2 years of age and older ', '(1.1)', 'Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ', '(1.2)', 'Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older ', '(1.3)', 'Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. ', 'Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older.', '\n                           ', 'Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp‰Ûªs montelukast tablet products. However, due to Merck Sharp & Dohme Corp‰Ûªs marketing exclusivity rights, this drug product is not labeled with that pediatric information', 'Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. ']",RHINITIS,MONTELUKAST,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_4483,,DB00471,3489a7de-e6b4-4c7c-8837-958d692a29bb.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
56.0,"
                     
Parenteral:

                     
Sedatives.

Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks (See ‰ÛÏ
Clinical Pharmacology
Preanesthetics.

Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics.
",ECLAMPSIA,Pentobarbital,"indication_symptomatic_relief
indication_symptomatic_relief
indication_treatment",Indication: Symptomatic Relief,Indication: Treatment,Indication: Symptomatic Relief,DOID_13593,,DB00312,ba9a6d07-599a-410d-95d4-83e2ae663c35.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
57.0,"Azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.
Azelastine hydrochloride nasal spray is an H1-receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older. (
1",RHINITIS,AZELASTINE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_4483,,DB00972,50bc8185-bcd7-20a7-abe8-cf06810e6a79.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
58.0,"Fexofenadine hydrochloride is an H1-receptor antagonist indicated for:
‰Û¢ Relief of symptoms associated with seasonal allergic rhinitis in patients 6 years of age and older (
1.1)
‰Û¢ Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in patients 6 years of age and older (
1.2)
Fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 
Fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 of age and older .",RHINITIS,FEXOFENADINE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_4483,,DB00950,2db62c07-21be-4378-82fc-a1bd9dc6e3ba.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
59.0,"Carefully consider the potential benefits and risks of etodolac extended-release tablets, USP and other treatment options before deciding to use etodolac extended-release tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see 

                        
WARNINGS
Etodolac extended-release tablets, USP are indicated:
*åÊåÊåÊ For relief of signs and symptoms of juvenile arthritis
*åÊåÊåÊ For relief of the signs and symptoms of rheumatoid arthritis
*åÊåÊåÊ For relief of the signs and symptoms of osteoarthritis",ARTHRITIS,ETODOLAC,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_848,,DB00749,8bc073da-7e01-4e0f-91bf-e5440b31bd1f.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
60.0,"Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. 
Bexarotene capsules are a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.åÊ
(1)",LYMPHOMA,BEXAROTENE,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Treatment,Indication: Treatment,DOID_0060058,,DB00307,8102cbe3-c43e-4e49-bd13-2acbe511c093.xml,indication_symptomatic_relief,Indication: Treatment,2,Indication: Treatment,
61.0,"Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/ urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.",CYSTITIS,Flavoxate,"indication_symptomatic_relief
indication_symptomatic_relief
effect",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_1679,,DB01148,34c3850c-1be2-4a78-9339-b2647a94cc3a.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
62.0,"Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/ urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.",URETHRITIS,Flavoxate,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_1343,,DB01148,34c3850c-1be2-4a78-9339-b2647a94cc3a.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
63.0,"[""KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.\n"", 'LIMITATIONS OF USE:\n', '\n                     ', ""KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome.\n"", ""KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. ("", '1', None, None, '\n                           ', '\n                              ', 'Important Limitations of Use:']",CUSHING'S SYNDROME,MIFEPRISTONE,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Treatment,DOID_446,,DB00834,3599ebc6-5883-4986-8f76-61accb5ec415.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
64.0,"ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. (
1.1
ZONTIVITY

                              
",MYOCARDIAL INFARCTION,vorapaxar,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Indication: Treatment,Indication: Symptomatic Relief,DOID_5844,,DB09030,d01926a0-45d9-425e-8659-34b33664ed55.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
65.0,"Panretin gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi‰Ûªs sarcoma.  Panretin gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement).  There is no experience to date using Panretin gel with systemic anti-KS treatment.",AIDS,ALITRETINOIN,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,IDK,DOID_635,,DB00523,50ab2ed7-651c-4952-91d6-5011709ae429.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
66.0,"Clotrimazole lozenges are indicated for the local treatment of 
oropharyngeal candidiasis. The diagnoses should be confirmed by a KOH smear 
and/or culture prior to treatment.
Clotrimazole lozenges are also indicated prophylactically to reduce the 
incidence of oropharyngeal candidiasis in patients immunocompromised by 
conditions that include chemotherapy, radiotherapy, or steroid therapy utilized 
in the treatment of leukemia, solid tumors, or renal transplantation. There are 
no data from adequate and well-controlled trials to establish the safety and 
efficacy of this product for prophylactic use in patients immunocompromised by 
etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION.)",LEUKEMIA,CLOTRIMAZOLE,"indication_treatment
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_1240,,DB00257,abf93477-f551-4e30-ba94-b2981a9d90cd.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
67.0,"Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/ urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.",PROSTATITIS,Flavoxate,"indication_symptomatic_relief
indication_treatment
indication_symptomatic_relief",Indication: Symptomatic Relief,Inconsistent,Indication: Symptomatic Relief,DOID_14654,,DB01148,34c3850c-1be2-4a78-9339-b2647a94cc3a.xml,indication_symptomatic_relief,Indication: Symptomatic Relief,2,Indication: Symptomatic Relief,
69.0,"Patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions:
 Cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see 
 Warnings and Precautions (5.3)
 Previous treatment with maximum cumulative dose of anthracyclines [see 
 Warnings and Precautions (5)
 Hypersensitivity to epirubicin hydrochloride injection, other anthracyclines, or anthracenediones [see 
 Adverse Reactions (6.2)
  Patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: baseline neutrophil countÃƒÂ¥Ãƒ_less thanÃƒÂ¥Ãƒ_1500 cells/mm
 3; 
 4",CARDIOMYOPATHY,Epirubicin Hydrochloride,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_0050700,,DB00445,../DailyMedExtracter/prescription/temp_xml/4f954c6a-221b-494c-aea7-1a8c1b65e424.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
70.0,"Tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Tolterodine tartrate extended-release capsulesare also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [ ]
  
 see
 ,
  
 WARNINGS AND PRECAUTIONS (5.2)
 (5.3)
 (5.4)
 .
 Tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine. ( )
  
 4",GLAUCOMA,Tolterodine Tartrate,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_1686,,DB01036,../DailyMedExtracter/prescription/temp_xml/448e25c6-3351-4d69-a0c4-502a53d266c8.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
72.0,"In patients who are hypersensitive to the drug or its ingredients. Phenazopyridine is contraindicated in patients with renal insufficiency, severe liver disease, severe hepatitis or pyelonephritis of pregnancy. 
 It should be used cautiously in the presence of GI disturbances.",HEPATITIS,Phenazopyridine Hydrochloride,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_2237,,DB01438,../DailyMedExtracter/prescription/temp_xml/7e5431d9-b3cd-72a6-e053-2a91aa0af749.xml,indication_symptomatic_relief,Contraindication,3,,
74.0,"Pyrazinamide is contraindicated in persons:
 
  
 with severe hepatic damage.
  
 who have shown hypersensitivity to it.
  
 with acute gout.",GOUT,Pyrazinamide,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_13189,,DB00339,../DailyMedExtracter/prescription/temp_xml/81b8609e-208c-1797-e053-2991aa0ac0ad.xml,indication_symptomatic_relief,Contraindication,3,,
75.0,"Administration is contraindicated in patients with any of the 
 following: 
 ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_Hypersensitivity to cycloserine
 ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_Epilepsy
 ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_Depression, severe anxiety, or psychosis
 ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_Severe renal insufficiency
 ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_Excessive concurrent use of alcohol",ANXIETY,SEROMYCIN,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_2030,,DB00260,../DailyMedExtracter/prescription/temp_xml/b96be2a2-b801-45d0-99ca-001ab54caf51.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
77.0,"[None, 'Eszopiclone is contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema ', '[see Warnings and Precautions (', '5.2', None, 'Known hypersensitivity to eszopiclone (', '4']",ANGIOEDEMA,ESZOPICLONE,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_1558,,DB00402,../DailyMedExtracter/prescription/temp_xml/8664ca9c-b06f-4e2e-9864-1c7f01d5143e.xml,indication_symptomatic_relief,Contraindication,3,,
79.0,"Anuria.
 
 Hypersensitivity to any component of this product or to other sulfonamide-derived drugs.",ANURIA,Chlorothiazide Sodium,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,IDK,DOID_2983,,DB00880,../DailyMedExtracter/prescription/temp_xml/1dab3243-f1dc-467d-b341-72aea14a0cce.xml,indication_symptomatic_relief,Contraindication,0,,Contraindication
80.0,Pindolol tablets are contraindicated in: 1) bronchial asthma; 2) overt cardiac failure; 3) cardiogenic shock; 4) second and third degree heart block; 5) severe bradycardia. (See WARNINGS.),ASTHMA,Pindolol,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_2841,,DB00960,../DailyMedExtracter/prescription/temp_xml/9d26b0a5-1482-4d81-9c05-a410f2348306.xml,indication_symptomatic_relief,Contraindication,3,,
81.0,"['\n ', 'Ocular or periocular infections (', '4.1', None, 'Glaucoma (', '4.2', None, 'Torn or ruptured posterior lens capsule (', '4.3', None, 'Hypersensitivity (', '4.4', '\n ', 'OZURDEX', '\n ', '', '\xa0', '\n ', 'OZURDEX', '\n ', '', '\n ', 'OZURDEX', '', 'OZURDEX', '', '\n ', 'OZURDEX', '\n ', '', '[see Adverse Reactions (', '\n ', '6', ')]']",GLAUCOMA,OZURDEX,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_1686,,DB01234,../DailyMedExtracter/prescription/temp_xml/8d4c99e3-44e1-484d-809f-6611582eb3e0.xml,indication_symptomatic_relief,Contraindication,3,,
82.0,"Known hypersensitivity or idiosyncratic reactions to 
 sympathomimetics.
 Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and 
 severe hypertension, hyperthyroidism, and glaucoma.
 Highly nervous or agitated patients.
 Patients with a history of drug abuse.
 Patients taking other CNS stimulants, including monoamine oxidase inhibitors
 Tolerance to the anorectic effect of phendimetrazine develops 
 within a few weeks. When this occurs, its use should be discontinued; the 
 maximum recommended dose should not be exceeded.
 Use of phendimetrazine tartrate within 14 days following the administration 
 of monoamine oxidase inhibitors may result in a hypertensive crisis.
 Abrupt cessation of administration following prolonged high dosage results in 
 extreme fatigue and depression. Because of the effect on the central nervous 
 system, phendimetrazine may impair the ability of the patient to engage in 
 potentially hazardous activities such as operating machinery or driving a motor 
 vehicle; the patient should therefore be cautioned accordingly.",GLAUCOMA,Phendimetrazine Tartrate,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_1686,,DB01579,../DailyMedExtracter/prescription/temp_xml/281377de-81c3-4fec-96e9-7b426190c3f9.xml,indication_symptomatic_relief,Contraindication,3,,
83.0,"[None, 'Hypersensitivity to HydrALAZINE ; coronary artery disease; mitral valvular rheumatic heart disease.']",CORONARY ARTERY DISEASE,Hydralazine Hydrochloride,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_3393,,DB01275,../DailyMedExtracter/prescription/temp_xml/26a904df-7070-489e-b0e0-67167a817944.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
84.0,"['Propafenone hydrochloride is contraindicated in the following circumstances:', '\n ', 'Heart failure', None, 'Cardiogenic shock', None, 'Sinoatrial, atrioventricular, and intraventricular disorders of impulse generation or conduction\xa0(e.g., sick sinus node syndrome, AV block) in the absence of an artificial pacemaker', None, 'Known Brugada Syndrome', None, 'Bradycardia', None, 'Marked hypotension', None, 'Bronchospastic disorders or severe obstructive pulmonary disease', None, 'Marked electrolyte imbalance', '\n ', 'Heart failure (', '4', 'Cardiogenic shock (', '4', 'Sinoatrial, atrioventricular, and intraventricular disorders of impulse generation or conduction in the absence of pacemaker (', '4', None, 'Known Brugada Syndrome (', '4', None, 'Bradycardia (', '4', 'Marked hypotension (', '4', 'Bronchospastic disorders and severe obstructive pulmonary disease (', '4', None, 'Marked electrolyte imbalance (', '4']",BRUGADA SYNDROME,Propafenone HCl,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_0050451,,DB01182,../DailyMedExtracter/prescription/temp_xml/71d5cee6-245f-4d4a-8a59-e555c3ca4573.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
85.0,"Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules, uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia, bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS: Hyperprolactinemic States). In the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma (see PRECAUTIONS: Hyperprolactinemic States)and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When bromocriptine is being used to treat acromegaly, prolactinoma, or ParkinsonÃ¢â‚¬Â°Ãƒâ€ºÃ‚Âªs disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine is considered to be medically contraindicated.
 The drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the postpartum period the patient should be observed with caution.",CORONARY ARTERY DISEASE,Bromocriptine Mesylate,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_3393,,DB01200,../DailyMedExtracter/prescription/temp_xml/184b35b9-920f-4fea-a6c8-cdc6c38fa7df.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
86.0,"Cleviprex is contraindicated in patients with:
 
  
 Allergy to soy or eggs 
 (4.1)
 Defective lipid metabolism 
 (4.2)
 Severe aortic stenosis 
 (4.3)
 Cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products. 
 Cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.
 Cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery.",ACUTE PANCREATITIS,Cleviprex,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,IDK,DOID_2913,,DB04920,../DailyMedExtracter/prescription/temp_xml/84cd997c-d395-4231-af87-92745009da0b.xml,indication_symptomatic_relief,Contraindication,0,,Contraindication
87.0,"Antepartum use of Pitocin is contraindicated in any of the following circumstances: 
 
  
 Where there is significant cephalopelvic disproportion;
 In unfavorable fetal positions or presentations, such as transverse lies, which are undeliverable without conversion prior to delivery;
 In obstetrical emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention;
 In fetal distress where delivery is not imminent;
 Where adequate uterine activity fails to achieve satisfactory progress;
 Where the uterus is already hyperactive or hypertonic;
 In cases where vaginal delivery is contraindicated, such as invasive cervical carcinoma, active herpes genitalis, total placenta previa, vasa previa, and cord presentation or prolapse of the cord;
 In patients with hypersensitivity to the drug.",CARCINOMA,Pitocin,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",IDK,Inconsistent,IDK,DOID_305,,DB00107,../DailyMedExtracter/prescription/temp_xml/31b91b2c-ec6b-4b84-b017-0ee25bc576d8.xml,indication_symptomatic_relief,Contraindication,0,,Contraindication
90.0,"Nadolol tablets are contraindicated in bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see 
 
  
 WARNINGS",ASTHMA,NADOLOL,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_2841,,DB01203,../DailyMedExtracter/prescription/temp_xml/4c4790bc-780e-47d1-9e0d-39c8f6962b86.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
91.0,"Miglitol tablets are contraindicated in patients with:
 
  
 Diabetic ketoacidosis
 Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction, and in patients predisposed to intestinal obstruction
 Chronic intestinal diseases associated with marked disorders of digestion or absorption, or with conditions that may deteriorate as a result of increased gas formation in the intestine
 Hypersensitivity to the drug or any of its components",DIABETIC KETOACIDOSIS,Miglitol,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_1837,,DB00491,../DailyMedExtracter/prescription/temp_xml/17a6135f-ebee-4943-a5bf-b35df3d1ca27.xml,indication_symptomatic_relief,Contraindication,2,Contraindication,
92.0,"['Rizatriptan benzoate tablets are contraindicated in patients with: ', '\n ', 'Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.1)', ""Coronary artery vasospasm including Prinzmetal's angina \n \n \n "", '[see \n \n \n ', 'Warnings and Precautions (5.1)', 'History of stroke or transient ischemic attack (TIA) \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.4)', 'Peripheral vascular disease (PVD)\n \n \n ', ' [see \n \n \n ', 'Warnings and Precautions (5.5)', 'Ischemic bowel disease \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.5)', 'Uncontrolled hypertension \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.8)', 'Recent use (i.e., within 24 hours) of another 5-HT\n \n \n ', '1', ' [see \n \n \n ', 'Drug Interactions (7.2', '7.3)', 'Hemiplegic or basilar migraine. ', 'Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor \n \n \n ', '[see\xa0\n \n \n ', 'Drug Interactions (7.5)', 'Clinical Pharmacology (12.3)', 'Hypersensitivity to rizatriptan benzoate tablets (angioedema and anaphylaxis seen) \n \n \n ', '[see \n \n \n ', 'Adverse Reactions (6.2)', '\n ', 'History of ischemic heart disease or coronary artery vasospasm (\n \n \n ', '4', 'History of stroke or transient ischemic attack (\n \n \n ', '4', 'Peripheral vascular disease (\n \n \n ', '4', 'Ischemic bowel disease (\n \n \n ', '4', 'Uncontrolled hypertension (\n \n \n ', '4', 'Recent (within 24 hours) use of another 5-HT\n \n \n ', '1', '4', 'Hemiplegic or basilar migraine (\n \n \n ', '4', 'MAO-A inhibitor used in the past 2 weeks (\n \n \n ', '4', 'Hypersensitivity to rizatriptan \n \n \n ', None, None, '4']",CORONARY ARTERY VASOSPASM,Rizatriptan Benzoate,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_11840,,DB00953,../DailyMedExtracter/prescription/temp_xml/2086f746-f922-1af1-e054-00144ff88e88.xml,indication_symptomatic_relief,Contraindication,3,,
93.0,"Hypersensitivity to any component of this product.
 Dactinomycin for injection should not be given at or about the time of infection with chickenpox or herpes zoster because of the risk of severe generalized disease which may result in death.",HERPES ZOSTER,Dactinomycin,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_8536,,DB00970,../DailyMedExtracter/prescription/temp_xml/5e1a4e0b-d686-420b-e053-2a91aa0a57ee.xml,indication_symptomatic_relief,Contraindication,3,,
96.0,"Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis and myocardial ischemia.",COLITIS,Levsin,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,IDK,DOID_0060180,,DB00424,../DailyMedExtracter/prescription/temp_xml/7d5bdc22-6926-4c95-9029-ed6f59d9f14f.xml,indication_symptomatic_relief,Contraindication,0,,Contraindication
97.0,"Do not initiate in patients with constipation (
  
  
  
  
  
  
 4.1
 History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment (
  
  
  
  
  
  
 4.2
 Concomitant use of fluvoxamine (
  
  
  
  
  
  
 4.3
  Alosetron hydrochloride 
  
  
  
  
  
  
 should not be initiated
 [see Warnings and Precautions (
  
  
  
  
  
  
 5.1
  Alosetron hydrochloride is contraindicated in patients with a history of the following:
 
 
  
 chronic or severe constipation or sequelae from constipation
 
 intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions
 
 ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state
 
 Crohn's disease or ulcerative colitis
 
 diverticulitis
 
 severe hepatic impairment
 
  Concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold 
  
  
  
  
  
  
 [see Drug Interactions (
  
  
  
  
  
  
 7.1",COLITIS,Alosetron Hydrochloride,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Indication: Symptomatic Relief,Contraindication,IDK,DOID_0060180,,DB00969,../DailyMedExtracter/prescription/temp_xml/7d8ab83e-2a7c-3eb1-e053-2a91aa0a723a.xml,indication_symptomatic_relief,Contraindication,0,,Contraindication
100.0,"['\n ', 'History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) ', 'During or within 14 days following the administration of monoamine oxidase inhibitors ', 'Hyperthyroidism ', 'Glaucoma ', 'Agitated states ', 'History of drug abuse ', 'Pregnancy [see \n \n \n ', '\n ', 'Use in Specific Populations (8.1)', 'Nursing [see \n \n \n ', '\n ', 'Use in Specific Populations (8.3)', 'Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines', '\n ', 'History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) (\n \n \n ', None, '4', 'During or within 14 days following the administration of monoamine oxidase inhibitors (\n \n \n ', None, '4', 'Hyperthyroidism (\n \n \n ', None, '4', 'Glaucoma (\n \n \n ', None, '4', 'Agitated states (\n \n \n ', None, '4', 'History of drug abuse (\n \n \n ', '4', 'Pregnancy (\n \n \n ', '4', '8.1', 'Nursing (\n \n \n ', '4', '8.3', 'Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines (\n \n \n ', None, None, '4']",GLAUCOMA,Phentermine Hydrochloride,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_1686,,DB00191,../DailyMedExtracter/prescription/temp_xml/7d633912-6179-b99b-e053-2a91aa0af59a.xml,indication_symptomatic_relief,Contraindication,3,,
101.0,"Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process.
 When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering Aminocaproic Acid Injection.
 The following tests can be applied to differentiate the two conditions:
 
  
 
  
 Platelet count is usually decreased in DIC but normal in primary fibrinolysis.
 
  
 Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis.
 
  
 The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC.
 Aminocaproic Acid Injection must not be used in the presence of DIC without concomitant heparin.",DISSEMINATED INTRAVASCULAR COAGULATION,Aminocaproic Acid,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_11247,,DB00513,../DailyMedExtracter/prescription/temp_xml/0d90446f-1a39-4fba-93a3-56bc2186a521.xml,indication_symptomatic_relief,Contraindication,3,,
102.0,"Ocular or periocular infections (
 4.1
 Hypersensitivity (
 4.2
 YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
 
 YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.",HERPES SIMPLEX,YUTIQ,"indication_symptomatic_relief
indication_symptomatic_relief
indication_symptomatic_relief",Contraindication,Contraindication,Contraindication,DOID_8566,,DB00591,../DailyMedExtracter/prescription/temp_xml/6f11fd9c-cdcc-4c6e-ac97-020deb9470db.xml,indication_symptomatic_relief,Contraindication,3,,
2.0,"['\n ', 'CONTRAINDICATIONS', 'Patients with allergy to these drugs or other analogues (diclofenac). Patients with asthma. Like NSAIDS, acetylsalicylic acid and other drugs which inhibit prostagladin-synthesis may precipitate attacks of asthma, acute rhinitis or urticaria. Patients with active peptic ulcer.', None]",ACUTE RHINITIS,Aceclofenac,Indication: treatment,Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_10459,Clanza,DB06736,../DailyMedExtracter/prescription/temp_xml/730de348-1686-4017-804e-010fd87b1f84.xml,contraindication,Contraindication,2,Contraindication,
3.0,"['Adenosine injection is contraindicated in patients with: ', None, '\n ', 'Second- or third-degree AV block (except in patients with a functioning artificial pacemaker) ', '[see ', 'Warnings and Precautions (5.2)', 'Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) ', '[see ', 'Warnings and Precautions (5.2)', 'Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) ', '[see ', 'Warnings and Precautions (5.3)', 'Known hypersensitivity to adenosine injection ', '[see ', 'Warnings and Precautions (5.7)', '\n ', 'Second- or third-degree AV block (except in patients with a functioning artificial pacemaker) (', '4', 'Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) (', '4', 'Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) (', '4', 'Known hypersensitivity to adenosine injection (', '4']",AV BLOCK,ADENOSINE,Indication: treatment,Contraindication,Contraindication,Contraindication,DOID_0050820,Adenosine,DB00640,../DailyMedExtracter/prescription/temp_xml/6644663e-f233-4536-94af-d7dbab396abf.xml,contraindication,Contraindication,3,,
4.0,"Sotalol hydrochloride is contraindicated in patients with:
 
  
 
  
 Sinus bradycardia, sick sinus syndrome, second and third degree AV block, unless a functioning pacemaker is present
 
  
 Congenital or acquired long QT syndromes
 
  
 Cardiogenic shock or decompensated heart failure
 
  
 Serum potassium <4 mEq/L
 
  
 Bronchial asthma or related bronchospastic conditions
 
  
 Hypersensitivity to sotalol
 For the treatment of AFIB/AFL, sotalol hydrochloride is also contraindicated in patients with:
 
  
 
  
 Baseline QT interval >450 ms
 
  
 Creatinine clearance < 40 mL/min
 For the treatment of AFIB/AFL or ventricular arrhythmias
 
  
 
  
 Sinus bradycardia, 2
  
  
  
 nd
 rd
 4
 
  
 Congenital or acquired long QT syndrome, (
  
  
  
 4
 
  
 Serum potassium <4 mEq/L (
  
  
  
 4
 
  
 Cardiogenic shock, decompensated heart failure (
  
  
  
 4
 
  
 Bronchial asthma or related bronchospastic conditions (
  
  
  
 4
 
  
 Hypersensitivity to sotalol (
  
  
  
 4
 For the treatment of AFIB/AFL also contraindicated for:
 
  
 
  
 QT interval >450 ms (
  
  
  
 4
 
  
 Creatine clearance <40 ml/min (
  
  
  
 4",AV BLOCK,SOTALOL,Indication: treatment,Contraindication,Contraindication,Contraindication,DOID_0050820,Sotalol Hydrochloride,DB00489,../DailyMedExtracter/prescription/temp_xml/46df076d-4e39-6faa-e054-00144ff8d46c.xml,contraindication,Contraindication,3,,
5.0,"['Rizatriptan benzoate tablets are contraindicated in patients with: ', '\n ', 'Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.1)', ""Coronary artery vasospasm including Prinzmetal's angina \n \n \n "", '[see \n \n \n ', 'Warnings and Precautions (5.1)', 'History of stroke or transient ischemic attack (TIA) \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.4)', 'Peripheral vascular disease (PVD)\n \n \n ', ' [see \n \n \n ', 'Warnings and Precautions (5.5)', 'Ischemic bowel disease \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.5)', 'Uncontrolled hypertension \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.8)', 'Recent use (i.e., within 24 hours) of another 5-HT\n \n \n ', '1', ' [see \n \n \n ', 'Drug Interactions (7.2', '7.3)', 'Hemiplegic or basilar migraine. ', 'Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor \n \n \n ', '[see\xa0\n \n \n ', 'Drug Interactions (7.5)', 'Clinical Pharmacology (12.3)', 'Hypersensitivity to rizatriptan benzoate tablets (angioedema and anaphylaxis seen) \n \n \n ', '[see \n \n \n ', 'Adverse Reactions (6.2)', '\n ', 'History of ischemic heart disease or coronary artery vasospasm (\n \n \n ', '4', 'History of stroke or transient ischemic attack (\n \n \n ', '4', 'Peripheral vascular disease (\n \n \n ', '4', 'Ischemic bowel disease (\n \n \n ', '4', 'Uncontrolled hypertension (\n \n \n ', '4', 'Recent (within 24 hours) use of another 5-HT\n \n \n ', '1', '4', 'Hemiplegic or basilar migraine (\n \n \n ', '4', 'MAO-A inhibitor used in the past 2 weeks (\n \n \n ', '4', 'Hypersensitivity to rizatriptan \n \n \n ', None, None, '4']",CORONARY ARTERY DISEASE,RIZATRIPTAN,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_3393,Rizatriptan Benzoate,DB00953,../DailyMedExtracter/prescription/temp_xml/2086f746-f922-1af1-e054-00144ff88e88.xml,contraindication,Contraindication,3,,
6.0,"TRULICITY is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (
 4
 5.1
 TRULICITY is contraindicated in patients with a prior serious hypersensitivity reaction to TRULICITY or any of the product components (
 4
 5.4
 
  
 Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢ Medullary Thyroid Carcinoma
 TRULICITY is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 
 [see Warnings and Precautions (
 5.1
 
  
 Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢ Hypersensitivity
 TRULICITY is contraindicated in patients with a prior serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY 
 [see Warnings and Precautions (
 5.4",CARCINOMA,DULAGLUTIDE,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_305,Trulicity,DB09045,../DailyMedExtracter/prescription/temp_xml/8075ae7f-386a-4a54-95d8-6da9811df93e.xml,contraindication,Contraindication,3,,
7.0,"GILENYA is contraindicated in patients who have:
 
  
 in the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization or Class III/IV heart failure
 a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker 
 [see Warnings and Precautions (5.1)]
 a baseline QTc interval Ã¢â‚¬Â°Ãƒ_Ã‚Â´ 500 msec
 
  
 cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
 had a hypersensitivity reaction to fingolimod or any of the excipients in GILENYA. Observed reactions include rash, urticaria and angioedema upon treatment initiation 
 [see Warnings and Precautions (5.13)]
 
  
 Recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure with hospitalization, or Class III/IV heart failure. (
 4
 History of Mobitz Type II 2
 nd
 rd
 4
 Baseline QTc interval Ã¢â‚¬Â°Ãƒ_Ã‚Â´ 500 msec. (
 4
 Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs. (
 4
 Hypersensitivity to fingolimod or its excipients. (
 4",AV BLOCK,FINGOLIMOD,Contraindication,Contraindication,Contraindication,Inconsistent,DOID_0050820,Gilenya,DB08868,../DailyMedExtracter/prescription/temp_xml/d6fe02c2-f285-4246-bbbf-db4f90b3ea73.xml,contraindication,Contraindication,2,Contraindication,
8.0,"Torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide tablets or to povidone.
 Torsemide tablets are contraindicated in patients who are anuric.
 Torsemide tablets are contraindicated in patients with hepatic coma.
 Hypersensitivity to torsemide tablets or povidone, anuria, and hepatic coma. (
  
 4",HEPATIC COMA,TORSEMIDE,Contraindication,Contraindication,Contraindication,Inconsistent,DOID_12550,Torsemide,DB00214,../DailyMedExtracter/prescription/temp_xml/841256fe-353c-e20e-e053-2a91aa0a3fc1.xml,contraindication,Contraindication,2,Contraindication,
9.0,"Methyldopa is contraindicated in patients:
 - with active hepatic disease, such as acute hepatitis and active cirrhosis.
 - with liver disorders previously associated with methyldopa therapy (see ).
  
 
  
 WARNINGS
 - with hypersensitivity to any component of this product.
 - on therapy with monoamine oxidase (MAO) inhibitors.",CIRRHOSIS,METHYLDOPA ANHYDROUS,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_5082,Methyldopa,DB00968,../DailyMedExtracter/prescription/temp_xml/29a33fb6-f519-4c20-8dc4-c5286f79fbd2.xml,contraindication,Contraindication,3,,
10.0,"Lindane Shampoo is contraindicated in premature infants and individuals with known uncontrolled seizure disorders.
 Lindane Shampoo is contraindicated for premature infants because their skin may be more permeable than that of full term infants and their liver enzymes may not be sufficiently developed to metabolize Lindane.
 Lindane Shampoo is also contraindicated for patients with crusted (Norwegian) scabies and other skin conditions (e.g., atopic dermatitis, psoriasis) that may increase systemic absorption of the drug.
 Lindane Shampoo is contraindicated for patients with known uncontrolled seizure disorders and for individuals with a known sensitivity to the product or any of its components.",DERMATITIS,LINDANE,Effect,Contraindication,Contraindication,Effect,DOID_2723,Lindane,DB00431,../DailyMedExtracter/prescription/temp_xml/c3b21190-72da-4a16-84c0-76317817bdf3.xml,contraindication,Contraindication,2,Contraindication,
11.0,"Loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients.
 Loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea.
 Loperamide hydrochloride is not recommended in infants below 24 months of age.
 Loperamide hydrochloride should not be used as the primary therapy:
 
  
 in patients with acute dysentery, which is characterized by blood in stools and high fever,
  
 in patients with acute ulcerative colitis,
  
 in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter,
  
 in patients with pseudomembranous colitis associated with the use of broad-spectrum antibiotics.",COLITIS,LOPERAMIDE,Contraindication,Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_0060180,Loperamide Hydrochloride,DB00836,../DailyMedExtracter/prescription/temp_xml/845fed39-d08b-2e56-e053-2a91aa0a4ae8.xml,contraindication,Contraindication,2,Contraindication,
12.0,"['\n ', 'Hypersensitivity to clarithromycin or any macrolide drug (\n \n \n ', '4.1', 'Cisapride, pimozide, lovastatin/simvastatin, ergotamine/dihydroergotamine (\n \n \n ', '4.2', '4.5', '4.6', 'History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (\n \n \n ', '4.3', 'Colchicine in renal or hepatic impairment (\n \n \n ', '4.4', '\n ', 'Hypersensitivity to clarithromycin or any macrolide drug (\n \n \n ', '4.1', 'Cisapride, pimozide, lovastatin/simvastatin, ergotamine/dihydroergotamine (\n \n \n ', '4.2', '4.5', '4.6', 'History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (\n \n \n ', '4.3', 'Colchicine in renal or hepatic impairment (\n \n \n ', '4.4', 'Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs \n \n \n ', '[see \n \n \n ', 'Warnings and Precautions (5.1)', 'Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated \n \n \n ', '[see \n \n \n ', 'Drug Interactions (7)', None, 'There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and \n \n \n ', 'torsades de pointes', 'Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin.', 'Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment.', 'Do not use clarithromycin tablets concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis \n \n \n ', '[see\xa0\n \n \n ', 'Warnings and Precautions (5.4)', 'Drug Interactions (7)', 'Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated \n \n \n ', '[see \n \n \n ', 'Drug Interactions (7)', 'For information about contraindications of other drugs indicated in combination with clarithromycin tablets, refer to their full prescribing information (contraindications section).']",CHOLESTATIC JAUNDICE,CLARITHROMYCIN,Effect,Effect,Effect,Effect,DOID_13603,Clarithromycin,DB01211,../DailyMedExtracter/prescription/temp_xml/4b7dbff8-c9af-1d20-e054-00144ff8d46c.xml,contraindication,Effect,3,,
14.0,"Use of Mefloquine Hydrochloride Tablets is contraindicated in patients with a known hypersensitivity to mefloquine or related compounds (e.g., quinine and quinidine) or to any of the excipients contained in the formulation. Mefloquine Hydrochloride Tablets should not be prescribed for prophylaxis in patients with active depression, a recent history of depression, generalized anxiety disorder, psychosis, or schizophrenia or other major psychiatric disorders, or with a history of convulsions.",GENERALIZED ANXIETY DISORDER,MEFLOQUINE,Indication: treatment,Contraindication,Contraindication,Contraindication,DOID_14320,Mefloquine Hydrochloride,DB00358,../DailyMedExtracter/prescription/temp_xml/b6ccbb82-3804-4f02-bf17-f07e22a8b02a.xml,contraindication,Contraindication,3,,
15.0,"Doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components.
 Doxapram should not be used in patients with epilepsy or other convulsive disorders.
 Doxapram is contraindicated in patients with proven or suspected pulmonary embolism.
 Doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction, muscle paresis (including neuromuscular blockade), flail chest, pneumothorax, acute bronchial asthma, pulmonary fibrosis, or other conditions resulting in restriction of the chest wall, muscles of respiration, or alveolar expansion.
 Doxapram is contraindicated in patients with evidence of head injury, cerebral vascular accident, or cerebral edema, and in those with significant cardiovascular impairment, uncompensated heart failure, severe coronary artery disease, or severe hypertension, including that associated with hyperthyroidism or pheochromocytoma. (See 
 
  
 WARNINGS",CORONARY ARTERY DISEASE,DOXAPRAM,Indication: treatment,Contraindication,Contraindication,IDK,DOID_3393,Dopram,DB00561,../DailyMedExtracter/prescription/temp_xml/3677a3fc-0838-4638-9fc3-b4e938780ac5.xml,contraindication,Contraindication,2,Contraindication,
16.0,"Zafirlukast tablets are contraindicated in patients who are hypersensitive to zafirlukast or any of its inactive ingredients.
 Zafirlukast tablets are contraindicated in patients with hepatic impairment including hepatic cirrhosis.",CIRRHOSIS,Zafirlukast,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_5082,Zafirlukast,DB00549,../DailyMedExtracter/prescription/temp_xml/b5fb9efb-3369-e1f9-384c-bd22e8ecad92.xml,contraindication,Contraindication,3,,
19.0,"NOCTIVA is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia:
 
  
 Hyponatremia or a history of hyponatremia 
 [see Warnings and Precautions (
 5.1
 Polydipsia
 Primary nocturnal enuresis 
 [see Use in Specific Populations (
 8.4
 Concomitant use with loop diuretics 
 [see Warnings and Precautions (
 5.1
 Concomitant use with systemic or inhaled glucocorticoids 
 [see Warnings and Precautions (
 5.1
 7.1
 Renal impairment with an estimated glomerular filtration rate (eGFR) below 50 mL/min/1.73 m
 2
 [see Use in Specific Populations (
 8.6
 Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion
 During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection
 NOCTIVA is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition:
 
  
 Congestive heart failure (New York Heart Association Class II to IV) 
 [see Warnings and Precautions (
 5.2
 Uncontrolled hypertension
 
  
 Hyponatremia or a history of hyponatremia (
 4
 Polydipsia (
 4
 Primary nocturnal enuresis (
 4
 Concomitant use with loop diuretics or systemic or inhaled glucocorticoids (
 4
 Estimated glomerular filtration rate below 50 mL/min/1.73 m
 2
 4
 Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (
 4
 During illnesses that can cause fluid or electrolyte imbalance (
 4
 New York Heart Association (NYHA) Class II-IV congestive heart failure (
 4
 Uncontrolled hypertension (
 4",CONGESTIVE HEART FAILURE,DESMOPRESSIN,Effect,Contraindication,Contraindication,Effect,DOID_6000,Noctiva,DB00035,../DailyMedExtracter/prescription/temp_xml/1e919787-67b7-4b45-9274-0ddbe6a8b674.xml,contraindication,Contraindication,2,Contraindication,
20.0,"Do not administer in the presence of diseases characterized by bleeding diathesis. Individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. Patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. Children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.",AUTOIMMUNE DISEASE,PERIPLANETA AMERICANA,Effect,Contraindication,IDK,Effect,DOID_417,American Cockroach,DB10417,../DailyMedExtracter/prescription/temp_xml/0c2a583c-28b8-4184-9f4d-9feba1e683c9.xml,contraindication,Contraindication,0,,Contraindication
22.0,"Bumetanide is contraindicated in anuria. Although bumetanide tablets can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide tablets. Bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected. Bumetanide is contraindicated in patients hypersensitive to this drug.",HEPATIC COMA,BUMETANIDE,Contraindication,Contraindication,Contraindication,Contraindication,DOID_12550,bumetanide,DB00887,../DailyMedExtracter/prescription/temp_xml/297a95f9-bf9d-4e77-8f76-41e511fa483c.xml,contraindication,Contraindication,3,,
24.0,"Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. HCG may cause fetal harm when administered to a pregnant woman. Combined HCG/PMS (pregnant mare's serum) therapy has been noted to induce high incidences of external congenital anomalies in the offspring of mice, in a dose-dependent manner. The potential extrapolation to humans has not been determined.",CARCINOMA,"GONADOTROPHIN, CHORIONIC",Contraindication,Contraindication,Contraindication,Contraindication,DOID_305,Novarel,DB09126,../DailyMedExtracter/prescription/temp_xml/7bd326f0-5c4c-2c4a-e053-2a91aa0a2752.xml,contraindication,Contraindication,3,,
25.0,"TEGSEDI is contraindicated in patients with:
 
  
 Platelet count below 100 x 10
 9
 [see Warnings and Precautions (
 5.1
 History of acute glomerulonephritis caused by TEGSEDI 
 [see Warnings and Precautions (
 5.2
 History of a hypersensitivity reaction to TEGSEDI 
 [see Warnings and Precautions (
 5.7
 
  
 Platelet count less than 100 x 10
 9
 4
 5.1
 History of acute glomerulonephritis caused by TEGSEDI (
 4
 5.2
 Patients with a history of a hypersensitivity reaction to TEGSEDI (
 4
 5.7",GLOMERULONEPHRITIS,INOTERSEN,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_2921,Tegsedi,DB14713,../DailyMedExtracter/prescription/temp_xml/922740f6-e540-49cc-8ecd-a705913fd8c4.xml,contraindication,Contraindication,3,,
26.0,"NOCTIVA is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia:
 
  
 Hyponatremia or a history of hyponatremia 
 [see Warnings and Precautions (
 5.1
 Polydipsia
 Primary nocturnal enuresis 
 [see Use in Specific Populations (
 8.4
 Concomitant use with loop diuretics 
 [see Warnings and Precautions (
 5.1
 Concomitant use with systemic or inhaled glucocorticoids 
 [see Warnings and Precautions (
 5.1
 7.1
 Renal impairment with an estimated glomerular filtration rate (eGFR) below 50 mL/min/1.73 m
 2
 [see Use in Specific Populations (
 8.6
 Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion
 During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection
 NOCTIVA is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition:
 
  
 Congestive heart failure (New York Heart Association Class II to IV) 
 [see Warnings and Precautions (
 5.2
 Uncontrolled hypertension
 
  
 Hyponatremia or a history of hyponatremia (
 4
 Polydipsia (
 4
 Primary nocturnal enuresis (
 4
 Concomitant use with loop diuretics or systemic or inhaled glucocorticoids (
 4
 Estimated glomerular filtration rate below 50 mL/min/1.73 m
 2
 4
 Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (
 4
 During illnesses that can cause fluid or electrolyte imbalance (
 4
 New York Heart Association (NYHA) Class II-IV congestive heart failure (
 4
 Uncontrolled hypertension (
 4",GASTROENTERITIS,DESMOPRESSIN,I dont know,Contraindication,Contraindication,IDK,DOID_2326,Noctiva,DB00035,../DailyMedExtracter/prescription/temp_xml/1e919787-67b7-4b45-9274-0ddbe6a8b674.xml,contraindication,Contraindication,2,Contraindication,
28.0,"CUVPOSA is contraindicated in:
 
  
  Patients with medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis).
  Patients taking solid oral dosage forms of potassium chloride. The passage of potassium chloride tablets through the gastrointestinal (GI) tract may be arrested or delayed with coadministration of CUVPOSA.
 
  
  Medical conditions that preclude anticholinergic therapy. (
 4
  Concomitant use of solid oral dosage forms of potassium chloride. (
 4",GLAUCOMA,GLYCOPYRRONIUM,Contraindication,Contraindication,Contraindication,Contraindication,DOID_1686,Cuvposa,DB00986,../DailyMedExtracter/prescription/temp_xml/d0729857-b70a-4f86-8c5e-3b5b96e6123e.xml,contraindication,Contraindication,3,,
29.0,"Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies and known hypersensitivity to the drug. It is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see 
 
  
 
  
 WARNINGS",CARDIAC ARREST,SUCCINYLCHOLINE,Contraindication,Effect,Effect,Contraindication,DOID_0060319,Quelicin,DB00202,../DailyMedExtracter/prescription/temp_xml/f03f24d8-b519-44b2-bfd1-a9e91498448e.xml,contraindication,Effect,2,Effect,
30.0,"['VIBERZI\xa0is contraindicated in patients:', '\n ', 'Without a gallbladder. These patients are at increased risk of developing serious adverse reactions of pancreatitis and/or sphincter of Oddi spasm ', '[see Warnings and Precautions (', '5.1', ', ', '5.2', ')]', None, 'With known or suspected\xa0biliary duct obstruction; or sphincter of Oddi disease or dysfunction. These patients are at increased risk for sphincter of Oddi spasm ', '[see Warnings and Precautions', '\xa0', '(', '5.1', ')].', None, 'With alcoholism, alcohol abuse or alcohol addiction, or in patients who drink more than 3 alcoholic beverages per day. These patients are at increased risk for acute pancreatitis ', '[see Warnings and Precautions (', '5.1', ')]', None, 'With a history of pancreatitis;\xa0or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction. These patients are at increased risk for acute pancreatitis\xa0', '[see Warnings and Precautions (', '5.1', ')]', None, 'With a known hypersensitivity reaction to VIBERZI ', '[see Warnings and Precautions (', '5.3', ')]', None, 'With severe hepatic impairment (Child-Pugh Class C).\xa0These patients are at risk for significantly increased plasma concentrations of eluxadoline ', '[see Use in Specific Populations (', '8.6', ')]', None, 'With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction. These patients may be at risk for severe complications of bowel obstruction\xa0', '[see Warnings and Precautions (', '5.4', ')]', '\n ', 'patients without a gallbladder (', '4', None, 'known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction (', '4', '\n ', 'alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages/day (', '4', None, 'a history of pancreatitis; structural diseases of the pancreas, including known or suspected pancreatic duct obstruction (', '4', None, 'patients with a known hypersensitivity reaction to VIBERZI (', '4', '5.3', None, 'severe hepatic impairment (Child-Pugh Class C) (', '4', '8.6', None, 'a history of chronic or severe constipation or sequelae from constipation,\xa0or known or suspected mechanical gastrointestinal obstruction (', '4']",CONSTIPATION,ELUXADOLINE,Contraindication,Indication: Treatment,Contraindication,Contraindication,DOID_2089,Viberzi,DB09272,../DailyMedExtracter/prescription/temp_xml/a5e3ee80-684f-4951-a0fa-fa1ce8b5bd6b.xml,contraindication,Contraindication,2,Contraindication,
31.0,"KETEK is contraindicated in patients with myasthenia gravis.
 KETEK is contraindicated in patients with previous history of hepatitis and/or jaundice associated with the use of KETEK tablets, or any macrolide antibiotic.
 KETEK is contraindicated in patients with a history of hypersensitivity to telithromycin and/or any components of KETEK tablets, or any macrolide antibiotic.
 Concomitant administration of KETEK with cisapride or pimozide is contraindicated. (See 
 
  
 CLINICAL PHARMACOLOGY, Drug-drug Interactions
 
  
 PRECAUTIONS
 Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or hepatic impairment. (See 
 
  
 WARNINGS, Drug Interactions
 
  
 PRECAUTIONS, Drug interactions",HEPATITIS,telithromycin,Effect,Contraindication,Contraindication,Effect,DOID_2237,Ketek,DB00976,../DailyMedExtracter/prescription/temp_xml/ce3e7997-b925-4b07-994e-b2e699e0d3a1.xml,contraindication,Contraindication,2,Contraindication,
32.0,"Active hepatic disease, such as hepatitis and cirrhosis, is a contraindication for use of dantrolene sodium capsules. Dantrolene sodium capsules are contraindicated where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain or maintain increased function.",HEPATITIS,DANTROLENE,Indication: Symptomatic relief,Contraindication,Contraindication,Effect,DOID_2237,Dantrolene Sodium,DB01219,../DailyMedExtracter/prescription/temp_xml/cbece5e5-72b3-433f-84ae-03013ce93454.xml,contraindication,Contraindication,2,Contraindication,
34.0,"Isoniazid is contraindicated in patients who develop severe hypersensitivity reactions, including drug-induced hepatitis; previous isoniazid-associated hepatic injury; severe adverse reactions to isoniazid such as drug fever, chills, arthritis; and acute liver disease of any etiology.",HEPATITIS,ISONIAZID,Effect,Contraindication,Contraindication,Effect,DOID_2237,Isoniazid,DB00951,../DailyMedExtracter/prescription/temp_xml/75907d04-0c9d-4a6a-b8c0-7d88ab5ad337.xml,contraindication,Contraindication,2,Contraindication,
35.0,"MAVENCLAD is contraindicated:
 
  
 in patients with current malignancy 
 [see 
 Warnings and Precautions (5.1)
 in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each treatment course. May cause fetal harm 
 [see 
 Warnings and Precautions (5.2)
 Use in Specific Populations (8.1
 8.3)
 in patients infected with the human immunodeficiency virus (HIV
 ) [see 
 Warnings and Precautions (5.4)
 in patients with active chronic infections (e.g., hepatitis or tuberculosis) 
 [see 
 Warnings and Precautions (5.4)
 in patients with a history of hypersensitivity to cladribine 
 [see 
 Warnings and Precautions (5.8)
 in women intending to breastfeed on a MAVENCLAD treatment day and for 10 days after the last dose 
 [see 
 Use in Specific Populations (8.2)
 
  
 Patients with current malignancy. (
 4
 Pregnant women, and women and men of reproductive potential who do not plan to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each treatment course. (
 4
 8.3
 HIV infection. (
 4
 Active chronic infections (e.g., hepatitis or tuberculosis). (
 4
 History of hypersensitivity to cladribine. (
 4
 5.8
 Women intending to breastfeed on a MAVENCLAD treatment day and for 10 days after the last dose. (
 4
 8.2",HEPATITIS,Cladribine,Contraindication,Contraindication,Contraindication,Contraindication,DOID_2237,Mavenclad,DB00242,../DailyMedExtracter/prescription/temp_xml/673d345e-01f3-4692-b223-5f2199c1d78d.xml,contraindication,Contraindication,3,,
37.0,"Nateglinide tablets are contraindicated in patients with:ÃƒÂ¥Ãƒ_
 1. Known hypersensitivity to the drug or its inactive ingredients.ÃƒÂ¥Ãƒ_
 2. Type 1 diabetes.ÃƒÂ¥Ãƒ_
 3. Diabetic ketoacidosis. This condition should be treated with insulin.",DIABETIC KETOACIDOSIS,nateglinide,Contraindication,Contraindication,Contraindication,Contraindication,DOID_1837,Nateglinide,DB00731,../DailyMedExtracter/prescription/temp_xml/7a130a11-a0a6-b96d-6862-850a291401fd.xml,contraindication,Contraindication,3,,
38.0,"['Injectable midazolam in contraindicated in patients with a known hypersensitivity to the drug. Benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. Benzodiazepines may be used in patiens with open-angle glaucoma only if they are receiving appropriate therapy. Measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied.', 'Midazolam Injection is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form. Midazoalm Injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol. (See\xa0', '\n ', 'WARNINGS', '\n ', None, '\n ', '\ufeffPRECAUTIONS; PEDIATRIC USE']",EYE DISEASE,MIDAZOLAM,Contraindication,Contraindication,Contraindication,Contraindication,DOID_5614,Midazolam,DB00683,../DailyMedExtracter/prescription/temp_xml/a0b453d2-f15c-4464-a686-d503d06778e1.xml,contraindication,Contraindication,3,,
39.0,"Urocit
 
 
  
 In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride).
 In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication.
 In patients with peptic ulcer disease because of its ulcerogenic potential.
 In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Urocit
 
 
 In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia.
 
  
 Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (
 4
 Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture (
 4
 Patients with peptic ulcer disease (
 4
 Patients with active urinary tract infection (
 4
 Patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min) (
 4",CARDIAC ARREST,POTASSIUM CATION,Contraindication,Contraindication,Effect,Contraindication,DOID_0060319,UROCIT-K,DB01345,../DailyMedExtracter/prescription/temp_xml/09893986-19e0-4364-93ba-5fbc7e7d3eed.xml,contraindication,Contraindication,2,Contraindication,
40.0,"AFREZZA is contraindicated in patients with the following:
 
  
 During episodes of hypoglycemia
 Chronic lung disease, such as asthma or chronic obstructive pulmonary disease (COPD), because of the risk of acute bronchospasm 
 [
 
  
 Warnings and Precautions (5.1)
 Hypersensitivity to regular human insulin or any of the AFREZZA excipients 
 [see 
 Warnings and Precautions (5.7)
 
  
 During episodes of hypoglycemia (
 4
 Chronic lung disease, such as asthma, or chronic obstructive pulmonary disease (
 4
 Hypersensitivity to regular human insulin or any of the AFREZZA excipients (
 4",CHRONIC OBSTRUCTIVE PULMONARY DISEASE,INSULIN HUMAN|Insulin Human,Contraindication,Effect,Contraindication,Contraindication,DOID_3083,Afrezza,DB00030,../DailyMedExtracter/prescription/temp_xml/a9010b8f-12ec-4d6a-8a9f-9ad5827d18dd.xml,contraindication,Contraindication,2,Contraindication,
43.0,"Isoniazid is contraindicated in patients who develop severe hypersensitivity reactions, including drug-induced hepatitis; previous isoniazid-associated hepatic injury; severe adverse reactions to isoniazid such as drug fever, chills, arthritis; and acute liver disease of any etiology.",ARTHRITIS,ISONIAZID,Indication: Symptomatic relief,Contraindication,Effect,Effect,DOID_848,Isoniazid,DB00951,../DailyMedExtracter/prescription/temp_xml/75907d04-0c9d-4a6a-b8c0-7d88ab5ad337.xml,contraindication,Effect,2,Effect,
44.0,"Hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules, uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia, bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS: Hyperprolactinemic States). In the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma (see PRECAUTIONS: Hyperprolactinemic States)and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When bromocriptine is being used to treat acromegaly, prolactinoma, or ParkinsonÃ¢â‚¬Â°Ãƒâ€ºÃ‚Âªs disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine is considered to be medically contraindicated.
 The drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the postpartum period the patient should be observed with caution.",ECLAMPSIA,BROMOCRIPTINE,Effect,Effect,Contraindication,Contraindication,DOID_13593,Bromocriptine Mesylate,DB01200,../DailyMedExtracter/prescription/temp_xml/184b35b9-920f-4fea-a6c8-cdc6c38fa7df.xml,contraindication,Contraindication,2,Contraindication,
45.0,"['Carvedilol is contraindicated in the following conditions:', '\n ', 'Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol', 'Second- or third-degree AV block', 'Sick sinus syndrome', 'Severe bradycardia (unless a permanent pacemaker is in place)', 'Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol', 'Patients with severe hepatic impairment', 'Patients with a history of a serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol.', None, None, None, 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 Bronchial asthma or related bronchospastic conditions (\n \n \n ', '4', 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 Second- or third-degree AV block (\n \n \n ', '4', 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 Sick sinus syndrome (\n \n \n ', '4', 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 Severe bradycardia (unless permanent pacemaker in place) (\n \n \n ', '4', 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 Patients in cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy. (\n \n \n ', '4', 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 Severe hepatic impairment (\n \n \n ', '2.4', '4', 'Ã¢â‚¬Â°Ãƒâ€ºÃ‚Â¢\xa0 History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol (\n \n \n ', '4']",AV BLOCK,CARVEDILOL,Indication: Symptomatic relief,Indication: Symptomatic Relief,Contraindication,Contraindication,DOID_0050820,Carvedilol,DB01136,../DailyMedExtracter/prescription/temp_xml/231b19c0-5ee3-33c1-e054-00144ff88e88.xml,contraindication,Contraindication,2,Contraindication,
48.0,"Known or suspected carcinoma of the prostate or the male breast.
  
 Carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption).
  
 Pregnancy, because of possible masculinization of the fetus. Oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when given in doses 9 times the human dose.
  
 Nephrosis, the nephrotic phase of nephritis.
  
 Hypercalcemia.",HYPERCALCEMIA,OXANDROLONE,Indication: Symptomatic relief,Effect,Contraindication,Contraindication,DOID_12678,Oxandrolone,DB00621,../DailyMedExtracter/prescription/temp_xml/82ce9e1d-3287-cacf-e053-2a91aa0ae1ad.xml,contraindication,Contraindication,2,Contraindication,
50.0,"Hypersensitivity to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. 
 Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. 
 Long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.",ENCEPHALOPATHY,acetazolamide,Effect,Effect,Effect,Effect,DOID_936,Acetazolamide,DB00819,../DailyMedExtracter/prescription/temp_xml/521838b0-a10d-495f-a014-f9ff25a6b6f3.xml,contraindication,Effect,3,,
51.0,"[None, '\n ', 'Known hypersensitivity to the product (', '4.1', 'Marked anxiety, tension, or agitation (', '4.2', 'Glaucoma (', '4.3', 'Tics or a family history or diagnosis of TouretteÃ¢â‚¬Â°Ãƒâ€ºÃ‚Âªs syndrome (', '4.4', 'Do not use methylphenidate hydrochloride extended-release tablets in patients currently using or within 2 weeks of using an MAO inhibitor (', '4.5', 'Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been observed in patients treated with methylphenidate hydrochloride extended-release tablets. Therefore, methylphenidate hydrochloride extended-release tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product ', '[see Adverse Reactions (', '6.6', 'Methylphenidate hydrochloride extended-release tablets are contraindicated in patients with marked anxiety, tension, and agitation, since the drug may aggravate these symptoms. ', 'Methylphenidate hydrochloride extended-release tablets are contraindicated in patients with glaucoma. ', ""Methylphenidate hydrochloride extended-release tablets are contraindicated in patients with motor tics or with a family history or diagnosis of Tourette's syndrome "", '[see Adverse Reactions (', '6.4', 'Methylphenidate hydrochloride extended-release tablets are contraindicated during treatment with monoamine oxidase (MAO) inhibitors, and also within a minimum of 14 days following discontinuation of a MAO inhibitor (hypertensive crises may result) ', '[see Drug Interactions (', '7.1']",ANXIETY,METHYLPHENIDATE,Indication: Symptomatic relief,Effect,Contraindication,Indication: Symptomatic Relief,DOID_2030,Methylphenidate Hydrochloride,DB00422,../DailyMedExtracter/prescription/temp_xml/691884ee-1ba9-4470-b2cb-b84c4aaf94c0.xml,contraindication,Contraindication,0,,Contraindication
53.0,"['Rivastigmine tartrate capsules are contraindicated in patients with:', None, '\n ', 'known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation ', '[see ', 'Description (11)', 'a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing ', '[see ', 'Warnings and Precautions (5.2)', None, 'Isolated cases of generalized skin reactions have been described in postmarketing experience ', '[see ', 'Adverse Reactions (6.2)', None, '\n ', 'Known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation. ', '(4)', 'History of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing. ', '(4, ', '5.2)', None]",DERMATITIS,RIVASTIGMINE,Effect,Effect,Effect,Effect,DOID_2723,Rivastigmine Tartrate,DB00989,../DailyMedExtracter/prescription/temp_xml/35787807-49b2-6034-dcb0-36037574fb42.xml,contraindication,Effect,3,,
55.0,"['Esmolol hydrochloride injection is contraindicated in patients with:', None, '\n ', 'Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest \n \n \n ', '[\n \n \n ', 'see Warnings and Precautions (5.2)', 'Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest \n \n \n ', '[\n \n \n ', 'see Warnings and Precautions (5.2)', 'Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest \n \n \n ', '[\n \n \n ', 'see Warnings and Precautions (5.2)', 'Decompensated heart failure: May worsen heart failure. ', 'Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest. ', 'IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and esmolol hydrochloride in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving esmolol hydrochloride and intravenous verapamil.', 'Pulmonary hypertension: May precipitate cardiorespiratory compromise.', 'Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).', '\n ', 'Severe sinus bradycardia\xa0\n \n \n ', '(4)', 'Heart block greater than first degree\xa0\n \n \n ', '(4)', 'Sick sinus syndrome \n \n \n ', '(4)', 'Decompensated heart failure\xa0\n \n \n ', '(4)', 'Cardiogenic shock\xa0\n \n \n ', '(4)', 'Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to esmolol hydrochloride\xa0\n \n \n ', '(4,', '7)', 'Pulmonary hypertension \n \n \n ', '(4)', 'Known hypersensitivity to esmolol \n \n \n ', '(4)']",ATRIOVENTRICULAR BLOCK,ESMOLOL,Contraindication,Effect,Contraindication,Contraindication,DOID_0050820,Esmolol Hydrochloride,DB00187,../DailyMedExtracter/prescription/temp_xml/6bb9921c-a0fa-309f-e053-2a91aa0a1e5e.xml,contraindication,Contraindication,2,Contraindication,
56.0,"['Esomeprazole magnesium is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria [ ]. For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with esomeprazole magnesium, refer to the CONTRAINDICATIONS section of their package inserts.\n ', 'see Adverse Reactions (', ')\n ', '6', None, None, 'Patients with known hypersensitivity to proton pump inhibitors (PPIs) (angioedema and anaphylaxis have occurred). ( )\n ', '4']",BRONCHOSPASM,ESOMEPRAZOLE,Effect,Effect,Effect,Effect,DOID_1176,Esomeprazole Magnesium,DB00736,../DailyMedExtracter/prescription/temp_xml/50e2c3d5-7948-43bf-8995-5ea53105ef93.xml,contraindication,Effect,3,,
57.0,"Do not initiate in patients with constipation (
  
  
  
  
  
  
 4.1
 History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment (
  
  
  
  
  
  
 4.2
 Concomitant use of fluvoxamine (
  
  
  
  
  
  
 4.3
  Alosetron hydrochloride 
  
  
  
  
  
  
 should not be initiated
 [see Warnings and Precautions (
  
  
  
  
  
  
 5.1
  Alosetron hydrochloride is contraindicated in patients with a history of the following:
 
 
  
 chronic or severe constipation or sequelae from constipation
 
 intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions
 
 ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state
 
 Crohn's disease or ulcerative colitis
 
 diverticulitis
 
 severe hepatic impairment
 
  Concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold 
  
  
  
  
  
  
 [see Drug Interactions (
  
  
  
  
  
  
 7.1",CONSTIPATION,ALOSETRON,Contraindication,Contraindication,Contraindication,Contraindication,DOID_2089,Alosetron Hydrochloride,DB00969,../DailyMedExtracter/prescription/temp_xml/7d8ab83e-2a7c-3eb1-e053-2a91aa0a723a.xml,contraindication,Contraindication,3,,
58.0,"Edetate calcium disodium should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.",HEPATITIS,EDETIC ACID,Effect,Contraindication,Contraindication,Effect,DOID_2237,Calcium Disodium Versenate,DB00974,../DailyMedExtracter/prescription/temp_xml/143830d7-46a5-49a3-b8b2-457a59533008.xml,contraindication,Contraindication,2,Contraindication,
59.0,"['The use of LILETTA is contraindicated when one or more of the following conditions exist:', '\n ', 'Pregnancy or suspected pregnancy', None, 'For use as post-coital contraception (emergency contraception)', None, 'Congenital or acquired uterine anomaly, including fibroids, that distorts the uterine cavity\xa0and would be incompatible with correct IUS placement', None, 'Acute pelvic inflammatory disease (PID) or endometritis\xa0or a history of PID unless there has been a subsequent intrauterine pregnancy ', None, 'Infected abortion in the past 3 months', None, 'Known or suspected uterine or cervical neoplasia ', None, 'Known or suspected breast cancer or other hormone-sensitive cancer, now or in the past ', None, 'Uterine bleeding of unknown etiology', None, 'Untreated acute cervicitis or vaginitis, including bacterial vaginosis, known chlamydial or gonococcal cervical infection, or other lower genital tract infections until infection is controlled \xa0', None, 'Acute liver disease or liver tumor (benign or malignant)', None, 'Conditions associated with increased susceptibility to pelvic infections\xa0', '[see Warnings and Precautions (', '\n ', '5.4', ')]', None, 'A previously inserted IUS that has not been removed', None, 'Hypersensitivity to any component of LILETTA\xa0', '[see Adverse Reactions (', '\n ', '6.2', ')]', '\n ', 'Pregnancy or suspected pregnancy (', '4', None, 'Use for post-coital contraception (emergency contraception) (', '4', None, 'Congenital or acquired uterine anomaly that distorts the uterine cavity and\xa0would be incompatible with correct IUS placement (', '4', None, 'Acute pelvic inflammatory disease (PID) or endometritis\xa0or a history of PID unless there has been a subsequent intrauterine pregnancy (', '4', None, 'Infected abortion in the past 3 months (', '4', None, 'Known or suspected uterine or cervical neoplasia\xa0(', '4', None, 'Known or suspected breast cancer or other hormone-sensitive cancer (', '4', None, 'Uterine bleeding of unknown etiology (', '4', None, 'Untreated acute cervicitis or vaginitis\xa0or other lower genital tract infections (', '4', None, 'Acute liver disease or liver tumor (benign or malignant) (', '4', None, 'Increased susceptibility to pelvic infections (', '4', None, 'A previously inserted IUS that has not been removed (', '4', None, 'Hypersensitivity to any component of LILETTA (', '4']",ACUTE CERVICITIS,LEVONORGESTREL,Contraindication,Contraindication,Contraindication,Contraindication,DOID_10616,LILETTA,DB00367,../DailyMedExtracter/prescription/temp_xml/56207206-c9df-41bd-beda-58a97e4a8624.xml,contraindication,Contraindication,3,,
61.0,"Hypersensitivity (
 4.1
 Pregnancy unless used for treatment of advanced breast cancer (
 4.2
 Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in those patients who have a known hypersensitivity to GnRH, GnRH agonist analogues or any of the components in ZOLADEX 
 [see Warnings and Precautions (
 5.6
 ZOLADEX is contraindicated during pregnancy unless ZOLADEX is being used for palliative treatment of advanced breast cancer. ZOLADEX can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormone changes that occur with ZOLADEX treatment 
 [see Use in Specific Populations (
 8.1",BREAST CANCER,GOSERELIN,Indication: Symptomatic relief,Contraindication,Inconsistent,Indication: Treatment,DOID_1612,ZOLADEX,DB00014,../DailyMedExtracter/prescription/temp_xml/e4b76400-1cf4-406b-be6f-b40d0a0bd6f1.xml,contraindication,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
62.0,"Pregnancy (
 4.1
 8.1
 Use of simvastatin or lovastatin and CYP3A substrates with narrow therapeutic range (
 4.2
 Concurrent long-term corticosteroid use (
 4.3
 Women with history of unexplained vaginal bleeding (
 4.4
 Women with endometrial hyperplasia with atypia or endometrial carcinoma (
 4.4
 KORLYM is contraindicated in women who are pregnant. Pregnancy must be excluded before the initiation of treatment with KORLYM or if treatment is interrupted for more than 14 days in females of reproductive potential. Non-hormonal contraceptives should be used during and one month after stopping treatment in all women of reproductive potential. 
 [See Use in Specific Populations 
 8.8
 KORLYM is contraindicated in patients taking simvastatin, lovastatin, and CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, due to an increased risk of adverse events. 
 [See Drug Interactions (
 7.1
 12.3
 KORLYM is contraindicated in patients who require concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses (e.g., immunosuppression after organ transplantation) because KORLYM antagonizes the effect of glucocorticoids.
 
 KORLYM is contraindicated in the following:
 
 
  
 Women with a history of unexplained vaginal bleeding
 
 Women with endometrial hyperplasia with atypia or endometrial carcinoma
 
 KORLYM is contraindicated in patients with prior hypersensitivity reactions to mifepristone or to any of the product components.",ENDOMETRIAL CARCINOMA,MIFEPRISTONE,Indication: Symptomatic relief,Effect,Contraindication,IDK,DOID_2871,Korlym,DB00834,../DailyMedExtracter/prescription/temp_xml/3599ebc6-5883-4986-8f76-61accb5ec415.xml,contraindication,Contraindication,0,,Contraindication
64.0,"A.ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ Patients exhibiting idiosyncratic reactions to psoralen compounds.
 B.ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ Patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances. Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.
 C.ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ Patients with melanoma or with a history of melanoma.
 D.ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ Patients with invasive squamous cell carcinomas.
 E.ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ÃƒÂ¥Ãƒ_ Patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses.",ERYTHROPOIETIC PROTOPORPHYRIA,METHOXSALEN,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_13270,Methoxsalen,DB00553,../DailyMedExtracter/prescription/temp_xml/0b2d4ace-aa26-439d-b9d4-2ba1e16d2458.xml,contraindication,Contraindication,3,,
65.0,"Lorazepam Injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle (polyethylene glycol, propylene glycol, and benzyl alcohol), in patients with acute narrow-angle glaucoma, or in patients with sleep apnea syndrome. It is also contraindicated in patients with severe respiratory insufficiency, except in those patients requiring relief of anxiety and/or diminished recall of events while being mechanically ventilated. The use of Lorazepam Injection intra-arterially is contraindicated because, as with other injectable benzodiazepines, inadvertent intra-arterial injection may produce arteriospasm resulting in gangrene which may require amputation (see 
 
  
 WARNINGS
 Lorazepam Injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol. (SeeÃƒÂ¥Ãƒ_
 
  
 
  
 WARNINGS
 
  
 
  
 PRECAUTIONS - Pediatric Use",ANXIETY,LORAZEPAM,Effect,Effect,Inconsistent,Inconsistent,DOID_2030,Lorazepam,DB00186,../DailyMedExtracter/prescription/temp_xml/c17cb7b1-b0c4-4c0c-91bc-69f962303735.xml,contraindication,Indication: Symptomatic Relief,0,,Indication: Symptomatic Relief
71.0,"Do not administer in the presence of diseases characterized by bleeding diathesis. Individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. Patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. Children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.",AUTOIMMUNE DISEASE,GLYCERIN,Contraindication,Contraindication,Contraindication,IDK,DOID_417,Coca-Glycerine Control,DB09462,../DailyMedExtracter/prescription/temp_xml/fb54abb5-85cd-485f-9542-a2742a31bf72.xml,contraindication,Contraindication,2,Contraindication,
72.0,"Verapamil hydrochloride injection is contraindicated in:
 1. Severe hypotension or cardiogenic shock.
 2. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker).
 3. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker).
 4. Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy).
 5. Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction.
 6. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated.
 7. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS Ã¢â‚¬Â°Ãƒ_Ã‚Â´ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting.
 8. Known hypersensitivity to verapamil hydrochloride.",CONGESTIVE HEART FAILURE,VERAPAMIL,Effect,Contraindication,Contraindication,Effect,DOID_6000,VERAPAMIL HYDROCHLORIDE,DB00661,../DailyMedExtracter/prescription/temp_xml/74d94dbf-0568-6c15-e053-2991aa0ac6e4.xml,contraindication,Contraindication,2,Contraindication,
74.0,"Lindane Shampoo is contraindicated in premature infants and individuals with known uncontrolled seizure disorders.
 Lindane Shampoo is contraindicated for premature infants because their skin may be more permeable than that of full term infants and their liver enzymes may not be sufficiently developed to metabolize Lindane.
 Lindane Shampoo is also contraindicated for patients with crusted (Norwegian) scabies and other skin conditions (e.g., atopic dermatitis, psoriasis) that may increase systemic absorption of the drug.
 Lindane Shampoo is contraindicated for patients with known uncontrolled seizure disorders and for individuals with a known sensitivity to the product or any of its components.",ATOPIC DERMATITIS,LINDANE,Effect,Contraindication,Contraindication,Effect,DOID_3310,Lindane,DB00431,../DailyMedExtracter/prescription/temp_xml/c3b21190-72da-4a16-84c0-76317817bdf3.xml,contraindication,Contraindication,2,Contraindication,
80.0,"ZINBRYTA is contraindicated in patients with:
 
 
  
 Pre-existing hepatic disease or hepatic impairment, including ALT or AST at least 2 times the ULN, because ZINBRYTA could exacerbate existing liver dysfunction 
 [see Dosage and Administration (
 2.3
 5.1
 A history of autoimmune hepatitis or other autoimmune condition involving the liver 
 [see Warnings and Precautions (
 5.1
 A history of hypersensitivity to daclizumab or any other components of the formulation. Use in such patients may result in anaphylaxis or life-threatening multi-organ hypersensitivity 
 [see Warnings and Precautions (
 5.4
 
  
 Pre-existing hepatic disease or hepatic impairment, including ALT or AST at least 2 times the ULN (
 4
 History of autoimmune hepatitis or other autoimmune condition involving the liver (
 4
 History of hypersensitivity to daclizumab or any other component of the formulation (
 4",HEPATITIS,Daclizumab,Contraindication,Contraindication,Contraindication,Contraindication,DOID_2237,Zinbryta,DB00111,../DailyMedExtracter/prescription/temp_xml/44238333-9880-413b-9a9e-1f2b09e0fd6a.xml,contraindication,Contraindication,3,,
82.0,"['Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.', None, 'Agitated states.', 'Patients with a history of drug abuse.', 'Known hypersensitivity or idiosyncrasy to amphetamine.', 'In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine sulfate extended-release capsules. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products (', 'see ', '\n ', 'ADVERSE REACTIONS', 'Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis (', 'see\xa0', '\n ', 'WARNINGS', '\xa0and ', '\n ', 'Drug Interactions']",GLAUCOMA,DEXTROAMPHETAMINE,Effect,Contraindication,Contraindication,Contraindication,DOID_1686,Dextroamphetamine Sulfate,DB01576,../DailyMedExtracter/prescription/temp_xml/20dbb7f7-a1db-4b1c-a8d7-15b0c92cea19.xml,contraindication,Contraindication,3,,
83.0,"Glyburide tablets are contraindicated in patients:
 
  
 With known hypersensitivity the drug or any of its excipients.
 Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
 Type I diabetes mellitus.
 Concomitant administration of bosentan.
 
  
 WARNINGS
 
  
 SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY
 
  
 The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups. 
 
  
 UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2ÃƒÂ¥_ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of glyburide tablets and of alternative modes of therapy. 
 
  
 Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure",DIABETIC KETOACIDOSIS,GLYBURIDE,Contraindication,Contraindication,Contraindication,Contraindication,DOID_1837,Glyburide,DB01016,../DailyMedExtracter/prescription/temp_xml/11925cb1-aa2a-2f64-e054-00144ff88e88.xml,contraindication,Contraindication,3,,
85.0,"LOTEMAX ointment, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. 
 LOTEMAX ointment, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. 
 (
 4",HERPES SIMPLEX,LOTEPREDNOL,Indication: treatment,Contraindication,Contraindication,Contraindication,DOID_8566,Lotemax,DB00873,../DailyMedExtracter/prescription/temp_xml/eeb962de-2b01-4a46-9c54-738bd4205584.xml,contraindication,Contraindication,3,,
87.0,"['Methazolamide tablets therapy is contraindicated in situations in which sodium and/or potassium serum levels are depressed, in cases of marked kidney or liver disease or dysfunction, in adrenal gland failure, and in hyperchloremic acidosis. In patients with cirrhosis, use may precipitate the development of hepatic encephalopathy.', None, 'Long-term administration of methazolamide is contraindicated in patients with angle-closure glaucoma, since organic closure of the angle may occur in spite of lowered intraocular pressure.']",GLAUCOMA,METHAZOLAMIDE,Contraindication,Contraindication,Contraindication,Indication: Treatment,DOID_1686,METHAZOLAMIDE,DB00703,../DailyMedExtracter/prescription/temp_xml/77ede814-d3e3-364f-e053-2991aa0a5459.xml,contraindication,Contraindication,2,Contraindication,
89.0,"VEXOL 1% (rimexolone ophthalmic suspension) is contraindicated in epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases of the eye; acute purulent untreated infections which, like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons with hypersensitivity to any component of the formulation.",HERPES SIMPLEX,RIMEXOLONE,Contraindication,Contraindication,Contraindication,Contraindication,DOID_8566,Vexol,DB00896,../DailyMedExtracter/prescription/temp_xml/047301fe-73f6-356c-ec16-a1123037f239.xml,contraindication,Contraindication,3,,
91.0,"['Eletriptan hydrobromide tablets are contraindicated in patients with: ', None, '\n ', 'Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including PrinzmetalÃ¢â‚¬Â°Ãƒâ€ºÃ‚Âªs angina ', '[see Warnings and Precautions (', '5.1', ')]', 'Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders ', '[see Warnings and Precautions (', '5.2', ')]', 'History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke', ' [see Warnings and Precautions (', '5.4', ')]', 'Peripheral vascular disease', ' [see Warnings and Precautions (', '5.5', ')]', 'Ischemic bowel disease ', '[see Warnings and Precautions (', '5.5', ')]', 'Uncontrolled hypertension ', '[see Warnings and Precautions (', '5.8', ')]', 'Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine', '1', '1', '[see Drug Interactions (', '7.1', ')]', 'Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) ', '[see Warnings and Precautions (', '5.9', ')]', 'Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir ', '[see Drug Interactions (', '7.2', ') and Clinical Pharmacology (', '12.3', ')]', '\n ', 'History of coronary artery disease (CAD) or coronary artery vasospasm (', '4', 'Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (', '4', 'History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine (', '4', 'Peripheral vascular disease (', '4', 'Ischemic bowel disease (', '4', 'Uncontrolled hypertension (', '4', 'Within 24 hours of treatment with another 5-HT', '1', '4', 'Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) (', '4', 'Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir (', '4']",CORONARY ARTERY DISEASE,eletriptan,Contraindication,Contraindication,Contraindication,Contraindication,DOID_3393,eletriptan hydrobromide,DB00216,../DailyMedExtracter/prescription/temp_xml/1db654e0-2780-4a7f-9c2f-020f0a1a1fe2.xml,contraindication,Contraindication,3,,
92.0,"Active hepatic disease, such as hepatitis and cirrhosis, is a contraindication for use of dantrolene sodium capsules. Dantrolene sodium capsules are contraindicated where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain or maintain increased function.",CIRRHOSIS,DANTROLENE,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_5082,Dantrolene Sodium,DB01219,../DailyMedExtracter/prescription/temp_xml/cbece5e5-72b3-433f-84ae-03013ce93454.xml,contraindication,Contraindication,3,,
93.0,"Hypersensitivity
 Ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone 
 (see 
 WARNINGS Ã¢â‚¬Â°Ãƒâ€ºÃƒâ€™ Hypersensitivity
 
  
 Neonates
 
  
 
  
 Premature neonates
 Ceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).
 
  
 
  
 Hyperbilirubinemic neonates: 
 Hyperbilirubinemic neonates should not be treated with ceftriaxone for injection. Ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients.
 
  
 Neonates Requiring Calcium Containing IV Solutions
 Ceftriaxone for injection is contraindicated in neonates (Ã¢â‚¬Â°Ãƒ__ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium- containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium 
 (see 
 CLINICAL PHARMACOLOGY
 WARNINGS 
 DOSAGE AND ADMINISTRATION
 Cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium- containing fluids.
 In some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. There have been no similar reports in patients other than neonates.
 
  
 Lidocaine
 Intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. When lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. Refer to the prescribing information of lidocaine.",ENCEPHALOPATHY,CEFTRIAXONE,Contraindication,Contraindication,Effect,Effect,DOID_936,CEFTRIAXONE,DB01212,../DailyMedExtracter/prescription/temp_xml/f11612a1-dfdb-48f0-8d73-48ce1fd53e31.xml,contraindication,Effect,2,Effect,
94.0,"['Trospium chloride tablets are contraindicated in patients with:', None, '\n ', 'urinary retention', 'gastric retention', 'uncontrolled narrow-angle glaucoma.', 'known hypersensitivity to the drug or its ingredients. Angioedema, rash and anaphylactic reaction have been reported.', None, '\n ', 'Trospium chloride tablets are contraindicated in\n\t\n ', '\n ', 'patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions (\n ', '4', 'patients with known hypersensitivity (\n ', '4']",GLAUCOMA,TROSPIUM,Contraindication,Contraindication,Contraindication,Contraindication,DOID_1686,TROSPIUM CHLORIDE,DB00209,../DailyMedExtracter/prescription/temp_xml/7549848a-a783-0646-e053-2991aa0a5055.xml,contraindication,Contraindication,3,,
95.0,"Anuria, hepatic coma or precoma, known allergy or hypersensitivity to metolazone.",ANURIA,METOLAZONE,Contraindication,Contraindication,Contraindication,Contraindication,DOID_2983,Metolazone,DB00524,../DailyMedExtracter/prescription/temp_xml/20d39fb1-12c2-4010-8010-ef55d8f48a08.xml,contraindication,Contraindication,3,,
96.0,"Hypersensitivity to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. 
 Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. 
 Long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.",CIRRHOSIS,acetazolamide,Indication: treatment,Contraindication,Contraindication,Contraindication,DOID_5082,Acetazolamide,DB00819,../DailyMedExtracter/prescription/temp_xml/521838b0-a10d-495f-a014-f9ff25a6b6f3.xml,contraindication,Contraindication,3,,
97.0,"Chenodiol is contraindicated in the presence of know hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis or sclerosing cholangitits (see Warnings); a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye; radiopaque stones; or gallstone complications or compelling reasons for gallbladder surgery including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.
 
  
 Pregnancy Category X:
 Chenodiol may cause fetal harm when administered to a pregnant woman. Serious hepatic, renal and adrenal lesions occurred in fetuses of female Rhesus monkeys given 60 to 90 mg/kg/day (4 to 6 times the maximum recommended human dose, MRHD) from day 21 to day 45 of pregnancy. Hepatic lesions also occurred in neonatal baboons whose mothers had received 18 to 38 mg/kg ( 1 to 2 times the MRHD), all during pregnancy. Fetal malformations were not observed. Neither fetal liver damage nor fetal abnormalities occurred in reproduction studies in rats and hamsters. No human data are available at this time. Chenodiol is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.",CIRRHOSIS,CHENODIOL,Effect,Contraindication,Contraindication,Effect,DOID_5082,Chenodiol,DB06777,../DailyMedExtracter/prescription/temp_xml/9aca5e67-d2c3-4e21-a584-4d90cfc70bd4.xml,contraindication,Contraindication,2,Contraindication,
98.0,"Diltiazem hydrochloride injection is contraindicated in:
 
  
 Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker. 
 
 Patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker. 
 
 Patients with severe hypotension or cardiogenic shock. 
 
 Patients who have demonstrated hypersensitivity to the drug. 
 
 Intravenous diltiazem and intravenous beta-blockers should not be administered together or in close proximity (within a few hours). 
 
 Patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in WPW syndrome or short PR syndrome. As with other agents which slow AV nodal conduction and do not prolong the refractoriness of the accessory pathway (e.g., verapamil, digoxin), in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection. As such, the initial use of diltiazem hydrochloride injection should be, if possible, in a setting where monitoring and resuscitation capabilities, including DC cardioversion/defibrillation, are present (see 
 
  
 OVERDOSAGE
 Patients with ventricular tachycardia. Administration of other calcium channel blockers to patients with wide complex tachycardia (QRS Ã¢â‚¬Â°Ãƒ_Ã‚Â´0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. It is important that an accurate pretreatment diagnosis distinguish wide complex QRS tachycardia of superventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection.",AV BLOCK,DILTIAZEM,Effect,Contraindication,Contraindication,Contraindication,DOID_0050820,Diltiazem Hydrochloride,DB00343,../DailyMedExtracter/prescription/temp_xml/10d5a837-21c0-4173-945c-5742340f5381.xml,contraindication,Contraindication,3,,
99.0,"Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.",GLAUCOMA,ORPHENADRINE,Indication: Symptomatic relief,Contraindication,Contraindication,Contraindication,DOID_1686,Orphenadrine Citrate,DB01173,../DailyMedExtracter/prescription/temp_xml/f9cb8829-a59e-4205-bc32-8145376179a3.xml,contraindication,Contraindication,3,,
101.0,"Leflunomide tablets are contraindicated in patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets.
 Leflunomide tablets can cause fetal harm when administered to a pregnant woman. Leflunomide, when administered orally to rats during organogenesis at a dose of 15 mg/kg, was teratogenic (most notably anophthalmia or microophthalmia and internal hydrocephalus). The systemic exposure of rats at this dose was approximately 1/10 the human exposure level based on AUC. Under these exposure conditions, leflunomide also caused a decrease in the maternal body weight and an increase in embryolethality with a decrease in fetal body weight for surviving fetuses. In rabbits, oral treatment with 10 mg/kg of leflunomide during organogenesis resulted in fused, dysplastic sternebrae. The exposure level at this dose was essentially equivalent to the maximum human exposure level based on AUC. At a 1 mg/kg dose, leflunomide was not teratogenic in rats and rabbits.
 When female rats were treated with 1.25 mg/kg of leflunomide beginning 14 days before mating and continuing until the end of lactation, the offspring exhibited marked (greater than 90%) decreases in postnatal survival. The systemic exposure level at 1.25 mg/kg was approximately 1/100 the human exposure level based on AUC.
 Leflunomide tablets are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.",HYDROCEPHALUS,LEFLUNOMIDE,Indication: Symptomatic relief,Effect,Effect,Effect,DOID_10908,Leflunomide,DB01097,../DailyMedExtracter/prescription/temp_xml/be0d579b-3b66-4227-b532-b0ee186a24ad.xml,contraindication,Effect,3,,
1.0,"['DURLAZA is indicated to:', None, '\n                     ', 'Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina', 'Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack', '\n                     ', '\n                        ', 'Limitation of Use', 'DURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack\xa0\xa0', '(1)', '\n                           ', 'Limitation of Use', ':', '(1,', '\xa04)', None]",MYOCARDIAL INFARCTION,Aspirin,"indication_symptomatic_relief
effect
effect",Indication: Treatment,Indication: Treatment,Indication: Symptomatic Relief,DOID_5844,,DB00945,6461fd18-6b4d-809a-73f4-fd0c23a99291.xml,effect,Indication: Treatment,2,Indication: Treatment,
2.0,"INNOPRAN XL

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program‰Ûªs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmåÊHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
INNOPRAN XL is a beta adrenergic blocker indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (
1
Limitation of Use: INNOPRAN XL is not indicated for the treatment of hypertensive emergencies. (
1",MYOCARDIAL INFARCTION,PROPRANOLOL,"effect
effect
indication_treatment",Indication: Treatment,Indication: Treatment,Effect,DOID_5844,,DB00571,8a9095b7-48a2-4920-9b5e-08a05c21d089.xml,effect,Indication: Treatment,2,Indication: Treatment,
3.0,"
                     

                        
Pernicious anemia, both uncomplicated and accompanied by nervous system involvement.

                        
Dietary deficiency of Vitamin B
12
12

                        
Malabsorption of vitamin B
12
12
12

                        
Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B
12
Structural lesions leading to vitamin B
12

                        
Competition for Vitamin B
12
The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B
12
12

                        
Inadequate utilization of vitamin B
12

                        
For the Schilling Test.",PERNICIOUS ANEMIA,HYDROXOCOBALAMIN,"contraindication
effect
effect",Indication: Treatment,Indication: Treatment,Contraindication,DOID_13381,,DB00200,8aba3d27-2891-4595-85be-87a2cf1c5dd9.xml,effect,Indication: Treatment,2,Indication: Treatment,
5.0,"CaptoprilåÊTablets, USPåÊare indicated for the treatment of hypertension.
In using Captopril Tablets, USP, consideration should be given to the risk of neutropenia/agranulocytosis (see 

                              
WARNINGS
Captopril Tablets, USPåÊmay be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.
Captopril Tablets, USP are effective alone and in combination with otheråÊantihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.
Captopril Tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment.
Captopril Tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ‰ä_ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients.
Captopril Tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).
In considering use of Captopril Tablets, USP, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (seeåÊ

                              
WARNINGS: Head and Neck Angioedema

                              
Intestinal Angioedema",ANGIOEDEMA,CAPTOPRIL,"indication_treatment
effect
effect",Effect,Effect,Effect,DOID_1558,,DB01197,3e077a23-c652-4eb7-9c70-955f5418f648.xml,effect,Effect,3,,
6.0,"	Felodipine extended-release tablets, USPåÊare indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine.
	Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program‰Ûªs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
	Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
	Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
	Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
	Felodipine extended-release tablets, USPåÊmay be administered with other antihypertensive agents.",MYOCARDIAL INFARCTION,FELODIPINE,"effect
indication_treatment
effect",Indication: Treatment,Indication: Treatment,Effect,DOID_5844,,DB01023,6a3461ba-c842-4361-874c-4c2c0215d79e.xml,effect,Indication: Treatment,2,Indication: Treatment,
7.0,"	Felodipine extended-release tablets, USPåÊare indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine.
	Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program‰Ûªs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
	Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
	Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
	Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
	Felodipine extended-release tablets, USPåÊmay be administered with other antihypertensive agents.",STROKE,FELODIPINE,"effect
effect
indication_treatment",Indication: Treatment,Indication: Treatment,Effect,DOID_6713,,DB01023,6a3461ba-c842-4361-874c-4c2c0215d79e.xml,effect,Indication: Treatment,2,Indication: Treatment,
8.0,"
                     
In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action.
In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon.
To relieve hypertonicity of the uterine muscle.
To relax the spasm of biliary and uretered colic and bronchial spasm.
To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders.
To control the crying and laughing episodes in patients with brain lesions.
In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs.
In the management of peptic ulcer.
In anesthesia to control excessive salivation and bronchial secretions.
To control rhinorrhea of acute rhinitis or hay fever.
As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning.
In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare ""nerve gases"", large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated.",DIARRHEA,ATROPINE,"i_dont_know
effect
effect",Effect,Effect,Effect,DOID_13250,,DB00572,f8b6425e-e87a-40d3-880f-360dad30a97a.xml,effect,Effect,3,,
9.0,"ELIQUIS is a factor Xa inhibitor indicated:

                           
to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 
          
  
     
(1.1)
for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 
          
  
     
(1.2)
for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. 
          
  
     
(1.3
1.4
1.5)
ELIQUIS
         
 
  

ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 
ELIQUIS is indicated for the treatment of DVT.
ELIQUIS is indicated for the treatment of PE. 
ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy.",PULMONARY EMBOLISM,APIXABAN,"effect
effect
effect",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_9477,,DB06605,8519dcba-d2e4-ffb8-e053-2a91aa0a7ada.xml,effect,Indication: Treatment,3,,
10.0,"Fosinopril sodium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see 

                        
DOSAGE AND ADMINISTRATION
In using fosinopril sodium, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril sodium does not have a similar risk (see 

                        
WARNINGS
In considering use of fosinopril sodium, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non- blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see 

                        
WARNINGS
: 

                        
Head and Neck Angioedema
 and 

                        
Intestinal Angioedema",ANGIOEDEMA,FOSINOPRIL,"effect
effect
effect",Effect,Effect,Effect,DOID_1558,,DB00492,29914956-c794-4806-b038-f0784b9db3d3.xml,effect,Effect,3,,
11.0,"['\n                     ', '\n                        ', '\n                           ', None, '\n                           ', None, None, 'Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).', 'Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.', 'Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.', '\n                           ', None, '\n                           ', 'Limitations of Use ', 'Warfarin sodium tablets, USP have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.', ' Warfarin sodium is indicated for:', '\n                           ', ' Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism ', '(1)', ' Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement ', '(1)', ' Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction ', '(1)', '\n                              ', 'Limitation of Use', ' Warfarin sodium tablets, USP has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. ', '(1)']",STROKE,WARFARIN,"effect
indication_treatment
effect",Indication: Treatment,Indication: Treatment,IDK,DOID_6713,,DB00682,569f166d-b427-4409-9418-8432052de580.xml,effect,Indication: Treatment,2,Indication: Treatment,
12.0,"Clopidogrel tablets are a P2Y                 
         
 
    
12

                           
Acute coronary syndrome                    
          
  
     

                                 
For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (                          
            
    
       
1.1
For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (                          
            
    
       
1.1
Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (                    
          
  
     
1.2

                           

                              
Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin           . Clopidogrel . Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin           . Clopidogrel . 

                              
Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin.Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin.Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin.Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin.

                           
In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke.",MYOCARDIAL INFARCTION,CLOPIDOGREL,"indication_treatment
effect
effect",Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_5844,,DB00758,7df4a376-157d-655e-e053-2991aa0aff28.xml,effect,Indication: Treatment,3,,
13.0,"['\n                     ', 'Hypertension', 'Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.', 'In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see ', 'WARNINGS', '\n                     ', 'Angioedema in Black Patients', 'Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.', None]",ANGIOEDEMA,QUINAPRIL,"contraindication
effect
effect",Effect,Effect,Effect,DOID_1558,,DB00881,461bf92c-0ad0-4e99-8542-6dc6bfbde5f1.xml,effect,Effect,3,,
16.0,"[None, '\n                     ', 'Hypertension:', None, 'Trandolapril tablets are indicated for the treatment of hypertension. They \nmay be used alone or in combination with other antihypertensive medication such \nas hydrochlorothiazide.', 'In considering the use of trandolapril tablets, it should be noted that in \ncontrolled trials ACE inhibitors (for which adequate data are available) cause a \nhigher rate of angioedema in black than in non-black patients. (See ', '\n                        ', 'Warnings: Angioedema', 'When using trandolapril tablets, consideration should be given to the fact \nthat another angiotensin converting enzyme inhibitor, captopril, has caused \nagranulocytosis, particularly in patients with renal impairment or \ncollagen-vascular disease. Available data are insufficient to show that \ntrandolapril tablets do not have a similar risk. (See ', '\n                        ', 'WARNINGS']",ANGIOEDEMA,TRANDOLAPRIL,"indication_treatment
effect
effect",Effect,Effect,Effect,DOID_1558,,DB00519,02953299-f03e-4305-9b78-8590f2ad4a46.xml,effect,Effect,3,,
17.0,"Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). 
Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. 
In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See 
WARNINGS.
In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See 
WARNINGS, Angioedema.",ANGIOEDEMA,ramipril,"effect
effect
effect",Effect,Effect,Effect,DOID_1558,,DB00178,00bdb48f-8b8f-4cc5-bb63-77213f2279cb.xml,effect,Effect,3,,
18.0,"[None, 'Enalapril maleate is indicated for the treatment of hypertension. ', None, 'Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive.', 'Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, ', '\n                           ', 'Heart Failure, Mortality Trials', ' for details and limitations of survival trials).', 'In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ‰ä_35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, ', '\n                           ', 'Heart Failure, Mortality Trials', ' for details and limitations of survival trials.)', None, None, 'In using enalapril maleate, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS.)', None, None, 'In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, ', '\n                           ', 'Head and Neck Angioedema', '.)']",ANGIOEDEMA,ENALAPRIL,"effect
effect
effect",Effect,Effect,Effect,DOID_1558,,DB00584,53ac99fe-8ff3-4a6f-b90e-d602e1019acb.xml,effect,Effect,3,,
22.0,"
                     
Stable Coronary Artery Disease
Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. 

                     
Hypertension 
Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 
When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See 

                        
WARNINGS
In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See 

                        
WARNINGS

                           
Head and Neck Angioedema",ANGIOEDEMA,PERINDOPRIL,"effect
contraindication
effect",Effect,Effect,Effect,DOID_1558,,DB00790,fbb31482-9ac8-48c6-b814-5d467f22051b.xml,effect,Effect,3,,
23.0,"CaptoprilåÊTablets, USPåÊare indicated for the treatment of hypertension.
In using Captopril Tablets, USP, consideration should be given to the risk of neutropenia/agranulocytosis (see 

                              
WARNINGS
Captopril Tablets, USPåÊmay be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.
Captopril Tablets, USP are effective alone and in combination with otheråÊantihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.
Captopril Tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment.
Captopril Tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ‰ä_ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients.
Captopril Tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).
In considering use of Captopril Tablets, USP, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (seeåÊ

                              
WARNINGS: Head and Neck Angioedema

                              
Intestinal Angioedema",NEUTROPENIA,CAPTOPRIL,"effect
contraindication
effect",Effect,Effect,Effect,DOID_1227,,DB01197,3e077a23-c652-4eb7-9c70-955f5418f648.xml,effect,Effect,3,,
27.0,"Ticlopidine Hydrochloride Tablets USP are indicated:

                     
to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.
                                
BOXED WARNING
WARNINGS
as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ).
                                
CLINICAL TRIALS",PURPURA,TICLOPIDINE,"effect
effect
effect",Effect,Effect,Effect,DOID_3326,,DB00208,c01a9760-cfb9-4d0d-9cf6-12d9deff463f.xml,effect,Effect,3,,
53.0,"['\n ', 'History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) ', 'During or within 14 days following the administration of monoamine oxidase inhibitors ', 'Hyperthyroidism ', 'Glaucoma ', 'Agitated states ', 'History of drug abuse ', 'Pregnancy [see \n \n \n ', '\n ', 'Use in Specific Populations (8.1)', 'Nursing [see \n \n \n ', '\n ', 'Use in Specific Populations (8.3)', 'Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines', '\n ', 'History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) (\n \n \n ', None, '4', 'During or within 14 days following the administration of monoamine oxidase inhibitors (\n \n \n ', None, '4', 'Hyperthyroidism (\n \n \n ', None, '4', 'Glaucoma (\n \n \n ', None, '4', 'Agitated states (\n \n \n ', None, '4', 'History of drug abuse (\n \n \n ', '4', 'Pregnancy (\n \n \n ', '4', '8.1', 'Nursing (\n \n \n ', '4', '8.3', 'Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines (\n \n \n ', None, None, '4']",CORONARY ARTERY DISEASE,PHENTERMINE,Contraindication,Contraindication,Contraindication,Effect,DOID_3393,Phentermine Hydrochloride,DB00191,../DailyMedExtracter/prescription/temp_xml/7d633912-6179-b99b-e053-2a91aa0af59a.xml,effect,Contraindication,2,Contraindication,
54.0,"Retinoids may cause fetal harm when administered to a pregnant 
 woman.
 In rats, tazaroteneÃƒÂ¥Ãƒ_0.05% gel, administered 
 topically
 2
 topically
 2
 de
 0-24h
 2
 0-24h
 2
 As with other retinoids, when tazarotene was given 
 orally
 de
 0-24h
 2
 0-24h
 2
 In a study of the effect of oral tazarotene on fertility and early embryonic 
 development in rats, decreased number of implantation sites, decreased litter 
 size, decreased numbers of live fetuses, and decreased fetal body weights, all 
 classic developmental effects of retinoids, were observed when female rats were 
 administered 2 mg/kg/day from 15 days before mating through gestation day 7. A 
 low incidence of retinoid-related malformations at that dose was reported to be 
 related to treatment. This dose produced an AUC
 de
 0-24h
 2
 0-24h
 2
 SYSTEMIC EXPOSURE TO TAZAROTENIC ACID IS DEPENDENT UPON THE EXTENT OF THE 
 BODY SURFACE AREA TREATED. IN PATIENTS TREATED TOPICALLY OVER SUFFICIENT BODY 
 SURFACE AREA, EXPOSURE COULD BE IN THE SAME ORDER OF MAGNITUDE AS IN THESE 
 ORALLY TREATED ANIMALS. ALTHOUGH THERE MAY BE LESS SYSTEMIC EXPOSURE IN THE 
 TREATMENT OF ACNE OF THE FACE ALONE DUE TO LESS SURFACE AREA FOR APPLICATION, 
 TAZAROTENE IS A TERATOGENIC SUBSTANCE, AND IT IS NOT KNOWN WHAT LEVEL OF 
 EXPOSURE IS REQUIRED FOR TERATOGENICITY IN HUMANS (SEE 
 CLINICAL PHARMACOLOGY: PHARMACOKINETICS
 There were thirteen reported pregnancies in patients who participated in 
 clinical trials for topical tazarotene. Nine of the patients were found to have 
 been treated with topical tazarotene, and the other four had been treated with 
 vehicle. One of the patients who was treated with tazarotene cream elected to 
 terminate the pregnancy for non-medical reasons unrelated to treatment. The 
 other eight pregnant women who were inadvertently exposed to topical tazarotene 
 during clinical trials subsequently delivered apparently healthy babies. As the 
 exact timing and extent of exposure in relation to the gestation times are not 
 certain, the significance of these findings is unknown.
 TAZORAC
 
 
 
 PRECAUTIONS: Pregnancy: Teratogenic 
 Effects
 TAZORAC",ACNE,TAZAROTENE,Contraindication,Indication: Treatment,Indication: Treatment,Indication: Treatment,DOID_6543,Tazorac,DB00799,../DailyMedExtracter/prescription/temp_xml/96f093aa-a72d-4459-b737-f9ac09dd03ca.xml,effect,Indication: Treatment,3,,
55.0,"Prednisolone acetate ophthalmic suspension 1% is contraindicated in acute untreated purulent ocular infections, in most viral diseasesÃƒÂ¥Ãƒ_of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis),ÃƒÂ¥Ãƒ_vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases ofÃƒÂ¥Ãƒ_ocular structures. 
 Prednisolone acetate ophthalmic suspension 1% is also contraindicatedÃƒÂ¥Ãƒ_in individuals with known or suspected hypersensitivity to any of the ingredients of thisÃƒÂ¥Ãƒ_preparation and to other corticosteroids.",HERPES SIMPLEX,PREDNISOLONE,Contraindication,Contraindication,Contraindication,Inconsistent,DOID_8566,PREDNISOLONE ACETATE,DB00860,../DailyMedExtracter/prescription/temp_xml/d54c592a-7e41-4578-8e8a-a0718ce65021.xml,effect,Contraindication,2,Contraindication,
56.0,"['Eletriptan hydrobromide tablets are contraindicated in patients with: ', None, '\n ', 'Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including PrinzmetalÃ¢â‚¬Â°Ãƒâ€ºÃ‚Âªs angina ', '[see Warnings and Precautions (', '5.1', ')]', 'Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders ', '[see Warnings and Precautions (', '5.2', ')]', 'History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke', ' [see Warnings and Precautions (', '5.4', ')]', 'Peripheral vascular disease', ' [see Warnings and Precautions (', '5.5', ')]', 'Ischemic bowel disease ', '[see Warnings and Precautions (', '5.5', ')]', 'Uncontrolled hypertension ', '[see Warnings and Precautions (', '5.8', ')]', 'Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine', '1', '1', '[see Drug Interactions (', '7.1', ')]', 'Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) ', '[see Warnings and Precautions (', '5.9', ')]', 'Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir ', '[see Drug Interactions (', '7.2', ') and Clinical Pharmacology (', '12.3', ')]', '\n ', 'History of coronary artery disease (CAD) or coronary artery vasospasm (', '4', 'Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (', '4', 'History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine (', '4', 'Peripheral vascular disease (', '4', 'Ischemic bowel disease (', '4', 'Uncontrolled hypertension (', '4', 'Within 24 hours of treatment with another 5-HT', '1', '4', 'Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) (', '4', 'Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir (', '4']",CORONARY ARTERY VASOSPASM,eletriptan,Effect,Contraindication,Contraindication,Contraindication,DOID_11840,eletriptan hydrobromide,DB00216,../DailyMedExtracter/prescription/temp_xml/1db654e0-2780-4a7f-9c2f-020f0a1a1fe2.xml,effect,Contraindication,3,,
59.0,"This product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma.
 This product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. This product should not be used in those persons showing hypersensitivity to any component of this preparation.",GLAUCOMA,ATROPINE,Indication: treatment,Contraindication,Contraindication,Contraindication,DOID_1686,Atropine Sulfate,DB00572,../DailyMedExtracter/prescription/temp_xml/ffb60cd8-0e95-42f6-ab77-a836e8af48e5.xml,effect,Contraindication,3,,
61.0,"Metoclopramide tablets are contraindicated: Metoclopramide tablets are contraindicated: 
 
  
 
  
 
  
 In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide 
  
  
  
 [see 
  
  
  
 
  
 Warnings and Precautions (
 
  
 5.1
 , 
 
  
 
  
 5.2
 
  
 )
 ]
 
  
 
  
 When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). 
 
  
 
  
 In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide tablets may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor 
  . ÃƒÂ¥Ãƒ_
  In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide tablets may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor 
  
  
  
 [see 
  
  
  
 
  
 Warnings and Precautions (
 
  
 5.5
 
  
 )
 
  
 
  
 In patients with epilepsy. Metoclopramide tablets may increase the frequency and severity of seizures 
  . 
  In patients with epilepsy. Metoclopramide tablets may increase the frequency and severity of seizures 
  
  
  
 [see 
  
  
  
 
  
 Adverse Reactions (
 
  
 6
 
  
 )
 
  
 
  
 In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm 
  .
  In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm 
  
  
  
 [see 
  
  
  
 
  
 Adverse Reactions (
 
  
 6
 
  
 )
 
  
 
  
 History of TD or dystonic reaction to metoclopramide (
  
  
  
 4
 
  
 When stimulation of gastrointestinal motility might be dangerousÃƒÂ¥Ãƒ_(
  
  
  
 4
 
  
 Pheochromocytoma, catecholamine-releasing paragangliomasÃƒÂ¥Ãƒ_(
  
  
  
 4
 
  
 EpilepsyÃƒÂ¥Ãƒ_(
  
  
  
 4
 
  
 Hypersensitivity to metoclopramideÃƒÂ¥Ãƒ_(
  
  
  
 4",EPILEPSY,METOCLOPRAMIDE,Effect,Contraindication,Contraindication,Effect,DOID_1826,Metoclopramide Hydrochloride,DB01233,../DailyMedExtracter/prescription/temp_xml/7536f9a4-3164-77ec-e053-2991aa0a6dc1.xml,effect,Contraindication,2,Contraindication,
62.0,"Naratriptan tablets are contraindicated in patients with:
 
  
 
  
   Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see 
 
  
 Warnings and Precautions (5.1)
  ] 
 
  
   Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see 
 
  
 Warnings and Precautions (5.2)
  ] 
 
  
   History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [see 
 
  
 Warnings and Precautions (5.4)
  ] 
 
  
   Peripheral vascular disease [see 
 
  
 Warnings and Precautions (5.5)
  ] 
 
  
   Ischemic bowel disease [see 
 
  
 Warnings and Precautions (5.5)
  ] 
 
  
   Uncontrolled hypertension [see 
 
  
 Warnings and Precautions (5.8)
  ] 
 
  
   Recent use (i.e., within 24 hours) of another 5-HT 
 1
  agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see 
 
  
 Drug Interactions
  (7.1, 7.2)] 
 
  
   Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see 
 
  
 Warnings and Precautions 
  (5.9)] 
 
  
   Severe renal or hepatic impairment [see 
 
  
 Use in Specific Populations
  (8.6, 8.7), 
 
  
 Clinical Pharmacology 
  (12.3)] 
 
  
 History of coronary artery disease or coronary artery vasospasm (4)
 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4)
 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4)
 Peripheral vascular disease (4)
 Ischemic bowel disease (4)
 Uncontrolled hypertension (4)
 
  
 Recent (within 24 hours) use of another 5-HT 
 1
  agonist (e.g., another triptan) or an ergotamine-containing medication (4)
 Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) (4)
 Severe renal or hepatic impairment (4)",CORONARY ARTERY DISEASE,NARATRIPTAN,Effect,Contraindication,Contraindication,Effect,DOID_3393,Naratriptan,DB00952,../DailyMedExtracter/prescription/temp_xml/7c83382b-f490-4a51-95ed-964f108d86bc.xml,effect,Contraindication,2,Contraindication,
65.0,"TRADJENTA is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity 
 
  
 [see Warnings and Precautions 
 (5.4)
  and Adverse Reactions 
 (6.1)
 ]
 History of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity 
 (4)",BRONCHIAL HYPERREACTIVITY,linagliptin,Effect,Contraindication,Effect,Effect,DOID_2841,Tradjenta,DB08882,../DailyMedExtracter/prescription/temp_xml/7ff9afdf-6b2b-48a4-8d36-b8fc27a3487a.xml,effect,Effect,2,Effect,
67.0,"Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.",DUODENAL OBSTRUCTION,ORPHENADRINE,I dont know,Contraindication,Contraindication,Contraindication,DOID_3558,Orphenadrine Citrate,DB01173,../DailyMedExtracter/prescription/temp_xml/f9cb8829-a59e-4205-bc32-8145376179a3.xml,effect,Contraindication,3,,
68.0,"Ursodiol capsules will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. Hence, patients with such stones are not candidates for ursodiol capsules therapy.
 Patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol capsules therapy.
 Allergy to bile acids.",CHOLANGITIS,URSADIOL,Effect,Indication: Treatment,Contraindication,Effect,DOID_9446,Ursodiol,DB14555,../DailyMedExtracter/prescription/temp_xml/7d7921dc-f117-dd8d-e053-2a91aa0a5d02.xml,effect,Contraindication,0,,Contraindication
69.0,"Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (
 See 
 
  
 PRECAUTIONS: Drug Interactions
 See 
 
  
 WARNINGS: CYP 3A4 Inhibitors
 Ergomar Sublingual Tablets may cause fetal harm when administered to pregnant women. Ergomar Sublingual Tablets are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this product, the patient should be apprised of the potential hazard to the fetus. Peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function and sepsis.
 Hypersensitivity to any of the components.",CORONARY HEART DISEASE,Ergotamine,Effect,Contraindication,Contraindication,Effect,DOID_3393,Ergomar,DB00696,../DailyMedExtracter/prescription/temp_xml/6ac058ea-d4f4-4fcd-83e1-5f2adb8652e6.xml,effect,Contraindication,2,Contraindication,
71.0,"['Rivastigmine tartrate capsules are contraindicated in patients with:', None, '\n ', 'known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation ', '[see ', 'Description (11)', 'a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing ', '[see ', 'Warnings and Precautions (5.2)', None, 'Isolated cases of generalized skin reactions have been described in postmarketing experience ', '[see ', 'Adverse Reactions (6.2)', None, '\n ', 'Known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation. ', '(4)', 'History of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing. ', '(4, ', '5.2)', None]",ALLERGIC CONTACT DERMATITIS,RIVASTIGMINE,Effect,Contraindication,Effect,Effect,DOID_3042,Rivastigmine Tartrate,DB00989,../DailyMedExtracter/prescription/temp_xml/35787807-49b2-6034-dcb0-36037574fb42.xml,effect,Effect,2,Effect,
78.0,"['\n ', 'Ischemic heart disease, coronary artery vasospasm, or other significant underlying cardiovascular disease (', '4.1', 'Cerebrovascular syndromes (e.g., history of stroke or TIA) (', '4.2', 'Peripheral vascular disease (including ischemic bowel disease) (', '4.3', 'Uncontrolled hypertension (', '4.4', 'Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT', '1', '4.5', '4.6', 'Hemiplegic or basilar migraine (', '4.7', 'Known hypersensitivity to almotriptan tablets (', '4.8', ""Do not use almotriptan tablets in patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or in patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease "", '[see Warnings and Precautions (', '5.1', 'Do not use almotriptan tablets in patients with cerebrovascular syndromes including (but not limited to) stroke of any type as well as transient ischemic attacks ', '[see Warnings and Precautions (', '5.3', 'Do not use almotriptan tablets in patients with peripheral vascular disease including (but not limited to) ischemic bowel disease ', '[see Warnings and Precautions (', '5.4', None, 'Because almotriptan tablets may increase blood pressure, do not use almotriptan tablets in patients with uncontrolled hypertension ', '[see Warnings and Precautions (', '5.7', 'Do not use almotriptan tablets and ergotamine-containing or ergot-derived medications like dihydroergotamine, ergotamine tartrate, or methysergide within 24 hours of each other ', '[see Drug Interactions (', '7.1', 'Almotriptan tablets and other 5-HT', '1', '[see Warnings and Precautions (', '5.1', '5.2', 'Do not use almotriptan tablets in patients with hemiplegic or basilar migraine.', 'Almotriptan tablets\xa0are contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients.']",HEART DISEASE,almotriptan,Indication: treatment,Contraindication,Contraindication,Inconsistent,DOID_114,almotriptan,DB00918,../DailyMedExtracter/prescription/temp_xml/a66362aa-a4c0-4b36-b77f-77b5d6826d9d.xml,effect,Contraindication,2,Contraindication,
79.0,"MAYZENT is contraindicated in patients who have:
 
  
 A CYP2C9*3/*3 genotype 
 [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.5)]
 In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure
 Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker 
 [see Warnings and Precautions (5.3)]
 
  
 Patients with a CYP2C9*3/*3 genotype (
 4
 In the last 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure (
 4
 Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker (
 4",AV BLOCK,SIPONIMOD,Effect,Contraindication,Contraindication,Effect,DOID_0050820,MAYZENT,DB12371,../DailyMedExtracter/prescription/temp_xml/44492772-5aed-4627-bd85-e8e89f308bb3.xml,effect,Contraindication,2,Contraindication,
80.0,"Allergy to any component of TUBERSOL or an anaphylactic or other allergic reaction to a previous test of tuberculin PPD is a contraindication to the use of TUBERSOL. (See 
 DESCRIPTION
 HOW SUPPLIED
 TUBERSOL should not be administered to:
 
  
 Persons who have had a severe reaction (e.g., necrosis, blistering, anaphylactic shock or ulcerations) to a previous TST,
 Persons with documented active tuberculosis or a clear history of treatment for TB infection or disease, (10)
 Persons with extensive burns or eczema.",ECZEMA,Tuberculin Purified Protein Derivative,Contraindication,Contraindication,Contraindication,Contraindication,DOID_2723,TUBERSOL,DB11601,../DailyMedExtracter/prescription/temp_xml/57d5fa05-f7af-48d5-90a7-39c0c2121134.xml,effect,Contraindication,3,,
85.0,"Do not administer in the presence of diseases characterized by bleeding diathesis. Individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. Patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. Children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.",AUTOIMMUNE DISEASE,HOUSE DUST,Effect,Effect,Inconsistent,IDK,DOID_417,A. Dust,DB10345,../DailyMedExtracter/prescription/temp_xml/89b69938-05fc-4bd8-9c55-4fb46e9018c7.xml,effect,Contraindication,0,,Contraindication
86.0,"Metopirone is contraindicated in patients with adrenal cortical insufficiency, or hypersensitivity to Metopirone or to any of its excipients.",ADRENAL CORTICAL INSUFFICIENCY,METYRAPONE,Indication: Symptomatic relief,Contraindication,Contraindication,Inconsistent,DOID_10493,Metopirone,DB01011,../DailyMedExtracter/prescription/temp_xml/80580507-b772-41bf-b70f-c27c379e7e8b.xml,effect,Contraindication,2,Contraindication,
88.0,"['Neostigmine is contraindicated in patients with:', '\n ', 'known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).\xa0 ', 'peritonitis or mechanical obstruction of the urinary or intestinal tracts. ', '\n ', 'Hypersensitivity to neostigmine (', '4', 'Peritonitis or mechanical obstruction of urinary or intestinal tracts (', '4', None]",BRONCHOSPASM,NEOSTIGMINE,Effect,Effect,Effect,Effect,DOID_1176,Neostigmine Methylsulfate,DB01400,../DailyMedExtracter/prescription/temp_xml/6448229c-e650-47ba-bb00-cba3604502c5.xml,effect,Effect,3,,
91.0,"Hypersensitivity to bethanechol chloride tablets, hyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or hypotension, vasomotor instability, coronary artery disease, epilepsy and parkinsonism. 
 Bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question, or in the presence of mechanical obstruction; when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful, as following recent urinary bladder surgery, gastrointestinal resection and anastomosis, or when there is possible gastrointestinal obstruction; in bladder neck obstruction, spastic gastrointestinal disturbances, acute inflammatory lesions of the gastrointestinal tract, or peritonitis; or in marked vagotonia.",EPILEPSY,Bethanechol,Effect,Effect,Contraindication,Contraindication,DOID_1826,Bethanechol Chloride,DB01019,../DailyMedExtracter/prescription/temp_xml/8813ae33-f2f0-4ffe-aa56-6bdb91247d73.xml,effect,Contraindication,2,Contraindication,
94.0,"Carteolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see 
 WARNINGS
 WARNINGS",CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CARTEOLOL,Effect,Contraindication,Contraindication,Effect,DOID_3083,Carteolol Hydrochloride,DB00521,../DailyMedExtracter/prescription/temp_xml/42565981-7e64-4080-8195-034fd5ca0565.xml,effect,Contraindication,2,Contraindication,
95.0,"Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See 
 
  
 WARNINGS
 PRECAUTIONS
 Information for Patients
 
  
 Pregnancy Category X
 Ribavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.
 Patients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.
 Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.
 Combination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. 
 See boxed CONTRAINDICATIONS AND WARNINGS. See 
 WARNINGS
 Ribavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.
 Patients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.",AUTOIMMUNE HEPATITIS,RIBAVIRIN,Effect,Effect,Inconsistent,Contraindication,DOID_2048,Ribavirin,DB00811,../DailyMedExtracter/prescription/temp_xml/cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml,effect,Contraindication,0,,Contraindication
97.0,"Active uveal inflammation.
 Most cases of angle-closure glaucoma without iridectomy, due to the possibility of increasing angle block.
 Hypersensitivity to the active or inactive ingredients.",GLAUCOMA,ECHOTHIOPHATE,Effect,Effect,IDK,Indication: Treatment,DOID_1686,Phospholine Iodide,DB01057,../DailyMedExtracter/prescription/temp_xml/7d5f18ab-49f0-4945-a0bf-2a88c353db79.xml,effect,Contraindication,0,,Contraindication
98.0,"['Propafenone hydrochloride is contraindicated in the following circumstances:', '\n ', 'Heart failure', None, 'Cardiogenic shock', None, 'Sinoatrial, atrioventricular, and intraventricular disorders of impulse generation or conduction\xa0(e.g., sick sinus node syndrome, AV block) in the absence of an artificial pacemaker', None, 'Known Brugada Syndrome', None, 'Bradycardia', None, 'Marked hypotension', None, 'Bronchospastic disorders or severe obstructive pulmonary disease', None, 'Marked electrolyte imbalance', '\n ', 'Heart failure (', '4', 'Cardiogenic shock (', '4', 'Sinoatrial, atrioventricular, and intraventricular disorders of impulse generation or conduction in the absence of pacemaker (', '4', None, 'Known Brugada Syndrome (', '4', None, 'Bradycardia (', '4', 'Marked hypotension (', '4', 'Bronchospastic disorders and severe obstructive pulmonary disease (', '4', None, 'Marked electrolyte imbalance (', '4']",AV BLOCK,PROPAFENONE,Effect,Contraindication,Contraindication,Effect,DOID_0050820,Propafenone HCl,DB01182,../DailyMedExtracter/prescription/temp_xml/71d5cee6-245f-4d4a-8a59-e555c3ca4573.xml,effect,Contraindication,2,Contraindication,
101.0,"Hypersensitivity to doxepin hydrochloride, inactive ingredients, or other dibenzoxepines. (
 4.1
  Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (
 4.2
  Untreated narrow angle glaucoma or severe urinary retention. (
 4.3
 Silenor is contraindicated in individuals who have shown hypersensitivity to doxepin HCl, any of its inactive ingredients, or other dibenzoxepines.
 Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors. Do not administer Silenor if patient is currently on MAOIs or has used MAOIs within the past two weeks. The exact length of time may vary depending on the particular MAOI dosage and duration of treatment.
 Silenor is contraindicated in individuals with untreated narrow angle glaucoma or severe urinary retention.",GLAUCOMA,doxepin,Effect,Effect,Contraindication,IDK,DOID_1686,Silenor,DB01142,../DailyMedExtracter/prescription/temp_xml/5205d855-ccf4-4d3f-be11-bda7476a62a3.xml,effect,Contraindication,0,,Contraindication
